Document:

Exhibit 10.6

Exhibit 10.6

CHANGE IN TERMS AGREEMENT

	 	 	 
	BORROWER:

	 	LENDER:
	Westmoreland Resources, Inc.

	 	FIRST INTERSTATE BANK
	PO Box 449

	 	Billings Office — Commercial Dept.
	Hardin, MT 59034-0449

	 	401 North 31st St.
	 

	 	P. O. Box 30918
	 

	 	Billings, MT 59116 
	 
	 	 
	 
	 	 
	Date of Agreement:

	 	11/6/09 
	Note Number:

	 	1100236355 

Description of Existing Indebtedness: Revolving line of credit note dated October 29, 2007 in the
original principal amount of $20,000,000.00. Current principal balance is $17,300,000.00.

Description of Collateral: All inventory, chattel paper, accounts, equipment and general intangibles.
Westmoreland Resources, Inc. stock.

Description of Change in Terms:

Interest rate remains at fully fluctuating Wall Street Journal Prime Rate (the “Index”), but will
have a floor of not less than 6.000% per annum.

Maturity Date is extended to November 18, 2010.

Monthly interest payments to continue beginning November 18, 2009.

1.000% extension/modification fee on the $20,000,000.00 payable on the date hereof.

Continuing Validity. Except as expressly changed by this Agreement, the terms of the original
obligation or obligations, including all agreements evidenced or securing the obligation(s), remain
unchanged and in full force and effect. Consent by Lender to this Agreement does not waive
Lender’s right to strict performance of the obligation(s) as changed, nor obligate Lender to make
any future change in terms. Nothing in this Agreement will constitute a satisfaction of the
obligation(s). It is the intention of Lender to retain as liable parties all makers and endorsers
of the original obligation(s), including accommodation parties, unless a party is expressly
released by Lender in writing. Any maker or endorser, including accommodation makers, will not be
released by virtue of this Agreement. If any person who signed the original obligation does not
sign this Agreement below, then all persons signing below acknowledge that this Agreement is given
conditionally, based on the representation to Lender that the non-signing party consents to the
changes and provisions of this Agreement or otherwise will not be released by it. This waiver
applies not only to any initial extension, modification or release, but also to all such subsequent
actions.

PRIOR TO SIGNING THIS AGREEMENT, BORROWER READ AND UNDERSTOOD ALL THE PROVISIONS OF THIS AGREEMENT.
BORROWER AGREES TO THE TERMS OF THE AGREEMENT AND ACKNOWLEDGES RECEIPT OF A COMPLETED COPY OF THE
AGREEMENT.

BORROWER:

WESTMORELAND RESOURCES, INC.

	 	 	 	 	 
	BY

	 	/s/ Douglas P. Kathol
 

DOUGLAS P. KATHOL
	 	 
	 

	 	VICE PRESIDENT OF DEVELOPMENT AND TREASURER	 	 

FIRST INTERSTATE BANK

	 	 	 	 	 
	BY

	 	/s/ Steve Tostenrud
 

STEVE TOSTENRUD, VICE PRESIDENTExhibit 10.7

Exhibit 10.7

CHANGE IN TERMS AGREEMENT

	 	 	 
	BORROWER:

	 	LENDER:
	Westmoreland Resources, Inc.

	 	FIRST INTERSTATE BANK
	PO Box 449

	 	Billings Office — Commercial Dept.
	Hardin, MT 59034-0449

	 	401 North 31st St.
	 

	 	P. O. Box 30918 
	 

	 	Billings, MT 59116 
	 
	 	 
	 
	 	 
	Date of Agreement:

	 	11/6/09 
	Note Number:

	 	1100236330 

Description of Existing Indebtedness: Promissory note dated October 29, 2007 in original principal
amount of $8,500.000.00. Current principal balance is $4,235,787.48.

Description of Collateral: All inventory, chattel paper, accounts, equipment and general intangibles.
Westmoreland Resources, Inc. stock.

Description of Change in Terms:

Lender will permit a one-time re-advance of principal, in one or more advances up to $3,764,212.60,
resulting in a total principal balance that may be outstanding of $8,000,000.00.

Interest rate remains at fully fluctuating Wall Street Journal Prime Rate (the “Index”), but will
have a floor of not less than 7.000% per annum.

Payment schedule is as follows:

Quarterly payments in the amount of $600,000.00 plus interest for 13 payments beginning January
29, 2010, with the balance plus interest due at maturity on January 29, 2013.

1.000% extension/modification fee on the $8,000,000.00 payable on the date hereof.

Continuing Validity. Except as expressly changed by this Agreement, the terms of the original
obligation or obligations, including all agreements evidenced or securing the obligation(s), remain
unchanged and in full force and effect. Consent by Lender to this Agreement does not waive
Lender’s right to strict performance of the obligation(s) as changed, nor obligate Lender to make
any future change in terms. Nothing in this Agreement will constitute a satisfaction of the
obligation(s). It is the intention of Lender to retain as liable parties all makers and endorsers
of the original obligation(s), including accommodation parties, unless a party is expressly
released by Lender in writing. Any maker or endorser, including accommodation makers, will not be
released by virtue of this Agreement. If any person who signed the original obligation does not
sign this Agreement below, then all persons signing below acknowledge that this Agreement is given
conditionally, based on the representation to Lender that the non-signing party consents to the
changes and provisions of this Agreement or otherwise will not be released by it. This waiver
applies not only to any initial extension, modification or release, but also to all such subsequent
actions.

PRIOR TO SIGNING THIS AGREEMENT, BORROWER READ AND UNDERSTOOD ALL THE PROVISIONS OF THIS AGREEMENT.
BORROWER AGREES TO THE TERMS OF THE AGREEMENT AND ACKNOWLEDGES RECEIPT OF A COMPLETED COPY OF THE
AGREEMENT.

BORROWER:

WESTMORELAND RESOURCES, INC.

	 	 	 	 	 
	BY

	 	/s/ Douglas P. Kathol
 

DOUGLAS P. KATHOL
	 	 
	 

	 	VICE PRESIDENT OF DEVELOPMENT AND TREASURER	 	 

FIRST INTERSTATE BANK

	 	 	 	 	 
	BY:

	 	/s/ Steve Tostenrud
 

STEVE TOSTENRUD, VICE PRESIDENTexv10w6

Exhibit 10.6

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

MATERIALS TRANSFER AGREEMENT

BY AND BETWEEN

NOVAVAX, INC.

AND

LABORATORIO AVI-MEX S.A. DE C.V.

DATED OCTOBER 19, 2009

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

TABLE OF CONTENTS

	 	 	 	 	 	 	 
	Article 1 Transfer of Materials	 	 	1	 
	Section 1.1
	 	Transfer	 	 	1	 
	Section 1.2
	 	Purpose	 	 	1	 
	Section 1.3
	 	Delivery of Materials	 	 	2	 
	Section 1.4
	 	Payment for Influenza Vaccine	 	 	2	 
	Section 1.5
	 	Evaluation; Restrictions on Transfer	 	 	2	 
	Article 2 Representations and Warranties	 	 	3	 
	Section 2.1
	 	Representations and Warranties of Each Party	 	 	3	 
	Section 2.2
	 	Additional Representations and Warranties of Novavax	 	 	3	 
	Section 2.3
	 	Additional Representations, Warranties and Covenants of Avimex	 	 	4	 
	Section 2.4
	 	Representation by Legal Counsel	 	 	5	 
	Section 2.5
	 	Disclaimer	 	 	5	 
	Article 3 MUTUAL COVENANTS	 	 	5	 
	Section 3.1
	 	Confidentiality.	 	 	5	 
	Section 3.2
	 	Compliance with Law	 	 	8	 
	Section 3.3
	 	Nonsolicitation of Employees	 	 	8	 
	Article 4 REGULATORY APPROVAL	 	 	8	 
	Section 4.1
	 	Regulatory Matters	 	 	8	 
	Article 5 Option	 	 	11	 
	Section 5.1
	 	Grant of Option	 	 	11	 
	Section 5.2
	 	Exercise of Option	 	 	11	 
	Section 5.3
	 	Effect of Option Exercise	 	 	11	 
	Section 5.4
	 	Escrow of Distribution Agreement	 	 	12	 
	Article 6 Right of First Negotiation	 	 	12	 
	Section 6.1
	 	Grant of Right of First Negotiation	 	 	13	 
	Article 7 Term and Termination	 	 	13	 
	Section 7.1
	 	Term	 	 	13	 
	Section 7.2
	 	Termination for Cause	 	 	13	 
	Section 7.3
	 	Effects of Termination	 	 	14	 
	Section 7.4
	 	Survival of Certain Obligations	 	 	15	 
	Article 8 Product Liability, Indemnification, and insurance	 	 	15	 
	Section 8.1
	 	Indemnification by Novavax	 	 	15	 
	Section 8.2
	 	Indemnification by Avimex	 	 	15	 
	Section 8.3
	 	Product Liability Claims	 	 	16	 
	Section 8.4
	 	Procedure	 	 	16	 
	Section 8.5
	 	Insurance	 	 	17	 
	Section 8.6
	 	Liability Limitations	 	 	17	 
	Article 9 MISCELLANEOUS.	 	 	17	 
	Section 9.1
	 	Governing Law; Jurisdiction; Dispute Resolution	 	 	17	 
	Section 9.2
	 	Definitions	 	 	19	 
	Section 9.3
	 	Force Majeure	 	 	21	 

 

 

	 	 	 	 	 	 	 
	Section 9.4
	 	Additional Approvals	 	 	22	 
	Section 9.5
	 	Waiver and Non-Exclusion of Remedies	 	 	22	 
	Section 9.6
	 	Notices	 	 	22	 
	Section 9.7
	 	Entire Agreement	 	 	23	 
	Section 9.8
	 	Amendment	 	 	23	 
	Section 9.9
	 	Assignment	 	 	24	 
	Section 9.10
	 	     No Benefit to Others	 	 	24	 
	Section 9.11
	 	     Counterparts	 	 	24	 
	Section 9.12
	 	     Severability	 	 	24	 
	Section 9.13
	 	     Further Assurance	 	 	24	 
	Section 9.14
	 	     Publicity	 	 	24	 
	Section 9.15
	 	     Relationship of the Parties	 	 	24	 

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

MATERIALS TRANSFER AGREEMENT

          This Materials Transfer Agreement (this “Agreement”) is entered into as of October 19,
2009 (the “Effective Date”) by and between Novavax, Inc., a corporation organized under the
laws of Delaware, United States (“Novavax”) and Laboratorio Avi-mex, S.A. de C.V., a
private company organized under the federal laws of Mexico (“Avimex”). Each of Novavax and
Avimex may be collectively referred to as the “Parties” and each individually as a
“
Party.”

          WHEREAS, the Parties entered into a Use of Protocol Agreement, dated as of August 21, 2009, a
copy of which is attached hereto;

          WHEREAS, Avimex desires to obtain Novavax’s Materials (as hereinafter defined) for the purpose
of (a) performing certain clinical trials in Mexico (the “Evaluation”) and (b) filing for
the necessary applications in the name and on behalf of Novavax to obtain the sanitary
registrations of the Influenza Vaccine (as hereinafter defined) from the Federal Commission For
Protection Against Sanitary Risks (“COFEPRIS”) in Mexico, to allow the commercial sale of
the Influenza Vaccine in Mexico (the “Territory”) as a vaccine in humans ((a) and (b)
referred to collectively as the “Purpose”); and

          WHEREAS, Avimex and Novavax have entered into that certain Confidentiality Agreement dated May
7, 2009 (the “Confidentiality Agreement”).

          NOW, THEREFORE, in consideration of the mutual agreements contained herein and intending to be
legally bound, the Parties agree as follows:

ARTICLE 1

TRANSFER OF MATERIALS

          Section 1.1 Transfer. Novavax shall transfer to Avimex amounts of the Influenza Vaccine
reasonably necessary to perform the Evaluation, including the Clinical Trial (as defined in Section
1.5(a)). For purposes of this Agreement, (a) “Influenza Vaccine” shall mean: Novavax’s
current monovalent intra-muscular H1N1 influenza vaccine containing a virus like particle (VLP)
consisting of [* * *] as designated as pandemic by the World Health Organization (WHO)
Collaborating Centers for Reference and Research on Influenza located at the Centers for Disease
Control and Prevention (CDC) in Atlanta, Georgia; and (b) “Materials” shall include
Influenza Vaccine, any associated know-how and data and any substance that is replicated or derived
therefrom. The Materials are proprietary to Novavax. Novavax will be free, at its sole
discretion, to distribute the Materials to others and to use the Materials for its own purposes
anywhere in the world.

          Section 1.2 Purpose. Avimex shall use the Materials solely for the Purpose in accordance
with this Agreement, and shall not use the Materials in any activities except as specifically and
expressly set forth in this Agreement. Avimex agrees that nothing herein shall

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

be deemed to grant any right or license, express or implied, under any Novavax patents,
know-how or other proprietary rights of Novavax whatsoever.

          Section 1.3 Delivery of Materials. Novavax will deliver the Influenza Vaccine necessary to
complete the Clinical Trial in a reasonable time to allow for a timely start of the Clinical Trial.
Avimex shall obtain all permits and approvals from any applicable Mexican governmental entity or
regulatory body necessary to import the Influenza Vaccine in Mexico. Notifications to the U.S.
Food and Drug Administration by Novavax regarding export and the receipt of certain U.S.
Certificates of Export may be necessary.

          Section 1.4 Payment for Influenza Vaccine.

     (a) Avimex shall pay Novavax [* * *]% of Novavax’s Production Costs for all Influenza
Vaccine transferred pursuant to this Agreement for purposes of conducting the clinical
trials (the “Transfer Price”). Novavax will include with each shipment of Influenza
Vaccine an invoice setting forth the Transfer Price for the Influenza Vaccine in each
shipment. Payment shall be due to Novavx thirty (30) days after Avimex’s receipt of the
Influenza Vaccine.

     (b) Avimex shall pay Novavax [* * *] upon execution of this Agreement. Such payment is
not refundable under any circumstances, but is creditable against certain payments that may
be owed under the Distribution Agreement.

          Section 1.5 Evaluation; Clinical Trial; Restrictions on Transfer.

     (a) Evaluation of the Product will include a clinical trial of the Product that will be
conducted in Mexico (the “Clinical Trial”). Avimex and Novavax have developed or
will develop the protocol for the Clinical Trial and the final protocol will be subject to
approval of Novavax. Novavax shall be the sponsor of the Clinical Trial. Avimex will
continue to have authority to appear before Regulatory Authorities on behalf of Novavax in
connection with the Clinical Trial and seeking Regulatory Approval, provided that Avimex is
in compliance with this Agreement, and Article 4 in particular.

     (b) Avimex has obtained or will obtain all regulatory approvals and licenses from any
governing body in Mexico that are required to conduct the Clinical Trial at its expense.
All such approvals and licenses will be in the name of Novavax, except as otherwise provided
by Novavax in writing.

     (c) Avimex will pay [* * *] for passthrough and site costs for the Clinical Trial and
for out of pocket expenses related to the Clinical Trial and other development and
regulatory costs, including regulatory counsel, up to a maximum [* * *]. Upon execution of
this Agreement, Novavax will pay to Avimex [* * *] which shall be used by Avimex to pay for
passthrough and site costs in excess of Avimex’s payment above. Upon determination to begin
phase 2 of the Clinical Trial (which must be agreed to by Novavax), Novavax will pay to
Avimex [* * *] which shall be used by Avimex to pay for

2

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

passthrough and site costs in excess of the prior payments set forth above. Avimex
will provide to Novavax a report reflecting all passthrough and site costs, out of pocket
expenses related to the Clinical Trial and other development and regulatory costs, including
regulatory counsel (totaling up to [* * *]), reflecting the payments by Avimex and Novavax
under this Section 1.5(c) with supporting documentation. Novavax shall also pay for all
CRO costs related to the Clinical Trial.

     (d) Subject to the prior written consent of Novavax and the prior approval of all
applicable Mexican Governmental Entities, Avimex may evaluate the Material in the Territory
in any facilities, by persons or entities, and under any protocols approved in advance by
Novavax. Any person or entity that evaluates the Material shall be subject to a written
agreement of confidentiality at least as restrictive as the provisions contained in this
Agreement and the Confidentiality Agreement and shall be obligated to assign to Avimex all
information and intellectual property generated in connection with any use of the Materials
or activities hereunder.

ARTICLE 2

REPRESENTATIONS AND WARRANTIES

          Section 2.1 Representations and Warranties of Each Party. As of the Effective Date, each of
Avimex and Novavax hereby represents and warrants to the other Party hereto as follows:

     (a) it is a corporation or entity duly organized and validly existing under the laws of
the state or other jurisdiction of its incorporation or formation;

     (b) the execution, delivery and performance of this Agreement by such Party has been
duly authorized by all requisite corporate or entity action and does not require any
shareholder or owner action or approval;

     (c) it has the power and authority to execute and deliver this Agreement and to perform
its obligations hereunder; and

     (d) the execution, delivery and performance by such Party of this Agreement and its
compliance with the terms and provisions does not and may not conflict with or result in a
breach of any of the terms and provisions of or require consent or constitute a default
under (i) a loan agreement, guaranty, financing agreement, agreement affecting a product or
other agreement or instrument binding or affecting it or its property; (ii) the provisions
of its charter or operative documents or bylaws; or (iii) any order, writ, injunction or
decree of any court or governmental authority entered against it or by which any of its
property is bound.

          Section 2.2 Additional Representations and Warranties of Novavax. Novavax hereby represents
and warrants to Avimex as of the Effective Date that:

3

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     (a) Novavax has the full right, power and authority to grant the right to perform the
Evaluation of the Materials granted to Avimex under this Agreement; and

     (b) By virtue of the License Agreement between Novavax and Wyeth Holdings Corporation
(“Wyeth”), dated July 5, 2007, Novavax does not infringe the patents owned by Wyeth that are
licensed to Novavax in such License Agreement.

          Section 2.3 Additional Representations, Warranties and Covenants of Avimex. Avimex hereby
represents, warrants and, where applicable, covenants to Novavax that as of the Effective Date:

     (a) Avimex has no products currently under development or commercialization for the
prevention of pandemic influenza in the Territory;

     (b) Avimex will not develop or commercialize any vaccine or other product in the
Territory for pandemic influenza in humans other than as contemplated by this Agreement; and

     (c) None of Avimex or any of its Subsidiaries or any of their respective
representatives has corruptly (within the meaning of Applicable Law) or otherwise illegally
offered, paid, promised to pay, or authorized the payment of any money, or offered, given,
promised to give, or authorized the giving of anything of value to: (1) any government or
similar official for purposes of (A) (i) influencing any act or decision of such official in
his or her official capacity, (ii) inducing such official to do or omit to do any act in
violation of the lawful duty of such official, or (iii) securing any improper advantage; or
(B) inducing such official to use his or her influence with a governmental entity or
regulatory body to affect or influence any act or decision of such governmental entity or
regulatory body, in order to assist Avimex or any of its Subsidiaries in obtaining or
retaining business for or with, or directing business to, any Person; (2) any political
party or official thereof or any candidate for political office for purposes of (A) (i)
influencing any act or decision of such party, official, or candidate in its or his or her
official capacity, (ii) inducing such party, official, or candidate to do or omit to do an
act in violation of the lawful duty of such party, official, or candidate, or (iii) securing
any improper advantage; or (B) inducing such party, official, or candidate to use its or his
or her influence with a governmental entity or regulatory body to affect or influence any
act or decision of such governmental entity or regulatory body in order to assist Avimex or
any of its Subsidiaries in obtaining or retaining business for or with, or directing
business to, any Person; or (3) any Person, while knowing that all or a portion of such
money or thing of value will be offered, given, or promised, directly or indirectly, to any
official, to any political party or official thereof, or to any candidate for political
office, for purposes of (A) (i) influencing any act or decision of such official, political
party, party official, or candidate in his or her or its official capacity, (ii) inducing
such official, political party, party official, or candidate to do or omit to do any act in
violation of the lawful duty of such official, political party, party official, or
candidate, or (iii) securing any improper advantage; or (B) inducing such official,
political party, party official, or candidate to use

4

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

his or her or its influence with a governmental entity or regulatory body to affect or
influence any act or decision of such governmental entity or regulatory body, in order to
assist Avimex or any of its Subsidiaries in obtaining or retaining business for or with, or
directing business to, any Person.

          Section 2.4 Representation by Legal Counsel. Each Party hereto represents that it has been
represented by legal counsel in connection with this Agreement and acknowledges that it has
participated in the drafting. In interpreting and applying the terms and provisions of this
Agreement, the Parties agree that no presumption will exist or be implied against the Party which
drafted such terms and provisions.

          Section 2.5 Disclaimer. Avimex acknowledges that the Materials are experimental in nature and
they are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY
OTHER WARRANTY, EXPRESS OR IMPLIED. NOVAVAX MAKES NO REPRESENTATION OR WARRANTY THAT THE USE OF THE
MATERIALS WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHTS. THE FOREGOING WARRANTIES OF
EACH PARTY ARE IN LIEU OF ANY OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION,
ANY IMPLIED WARRANTIES OF NONINFRINGEMENT, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED
WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE ALL OF WHICH ARE HEREBY SPECIFICALLY EXCLUDED AND
DISCLAIMED. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT,
MANUFACTURE OR COMMERCIALIZATION OF ANY PRODUCT UNDER THIS AGREEMENT WILL BE SUCCESSFUL. NOVAVAX
MAKES NO REPRESENTATION THAT ANY CLINICAL TRIALS CONDUCTED HEREUNDER WILL BE SUCCESSFUL.

ARTICLE 3

MUTUAL COVENANTS

          Section 3.1 Confidentiality.

     (a) Confidential Information. Except to the extent expressly permitted by this
Agreement and subject to the provisions of Section 3.1(b) and Section 3.1(c)
at all times during the Term and for five years following the expiration or termination of
this Agreement, each Party (a “Receiving Party”) (a) will keep completely
confidential and will not publish or otherwise disclose any Confidential Information
furnished to it by the other Party (a “Disclosing Party”), except to those of the
Receiving Party’s employees, Affiliates, consultants or representatives who have a need to
know such information (collectively, “Authorized Recipients”) to perform such
Party’s obligations hereunder and (b) will not use Confidential Information of the
Disclosing Party directly or indirectly for any purpose other than performing its
obligations hereunder. The Receiving Party will be liable for any breach by any of its
Authorized Recipients of the restrictions set forth in this Agreement. Notwithstanding the
foregoing, Novavax may disclose Confidential

5

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

Information of Avimex (i) as contemplated by Section 4.1(e) and (ii) to Third Party
Licensees to the extent necessary to comply with or conduct activities under written
arrangements with such Third Party Licensees provided that such arrangements include
obligations of confidentiality.

     (b) Exceptions to Confidentiality. The Receiving Party’s obligations set forth
in this Agreement will not extend to any Confidential Information of the Disclosing Party:

     (i) that is or hereafter becomes part of the public domain through no wrongful
act, fault or negligence on the part of a Receiving Party or its Authorized
Recipients;

     (ii) that is received from a Third Party without restriction and without breach
of any agreement or fiduciary duty between such Third Party and the Disclosing
Party;

     (iii) that the Receiving Party can demonstrate by competent evidence was
already in its possession without any limitation or restriction on use or disclosure
prior to its receipt from the Disclosing Party;

     (iv) that is generally made available to Third Parties by the Disclosing Party
without any restriction imposed by the Disclosing Party on disclosure, whether such
restriction is by contract, fiduciary duty or by operation of law; or

     (v) that the Receiving Party can demonstrate by competent evidence was
independently developed by the Receiving Party without any reference to Confidential
Information.

     (c) Authorized Disclosure. Each Party and its Authorized Recipients may
disclose Confidential Information to the extent that such disclosure is made in response to
a valid order, governmental inquiry, or request (each an “Order”) of a court of
competent jurisdiction or other agency, as applicable; provided, however, that the Receiving
Party must first have given notice to the Disclosing Party and given the Disclosing Party a
reasonable opportunity to quash such Order or to obtain a protective order requiring that
the Confidential Information and/or documents that are the subject of such Order be held in
confidence by such court or agency or, if disclosed, be used only for the purposes for which
the Order was issued; and provided further that if an Order is not quashed or a protective
order is not obtained, the Confidential Information disclosed in response to such Order will
be limited to that information that is legally required to be disclosed in such response to
such Order.

     (d) Notification. The Receiving Party will notify the Disclosing Party
immediately, and cooperate with the Disclosing Party as the Disclosing Party may

6

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

reasonably request, upon the Receiving Party’s discovery of any loss or compromise of
the Disclosing Party’s Confidential Information.

     (e) Destruction of Confidential Information. Upon the expiration or earlier
termination of this Agreement, the Receiving Party will (a) destroy all tangible embodiments
of Confidential Information of the Disclosing Party, including any and all copies thereof,
and those portions of any documents, memoranda, notes, studies, and analyses prepared by the
Receiving Party or its Authorized Recipients that contain, incorporate, or are derived from
such Confidential Information and provide written certification of such destruction to the
Disclosing Party in a form reasonably acceptable to the Disclosing Party, provided that the
legal department of the Receiving Party will have the right to retain one copy of any such
tangible embodiments for archival purposes, provided such copy will continue to be
maintained on a confidential basis subject to the terms of this Agreement, and (b)
immediately cease, and will cause its Authorized Recipients to cease, use of such
Confidential Information as well as any information or materials that contain, incorporate,
or are derived from such Confidential Information.

     (f) Use of Name and Disclosure of Terms. Each Party will keep the existence of,
the terms of, and the transactions covered by this Agreement confidential and will not
disclose such information to any other Person through a press release or otherwise, or
mention or otherwise use the name, insignia, symbol, trademark, trade name, or logotype of
the other Party or its Affiliates in any manner without the prior written consent of the
other Party in each instance (which will not be unreasonably withheld). The restrictions
imposed by this Section 3.1(f) will not prohibit either Party from making any disclosure
that is required by Applicable Law, rule, or regulation or the requirements of a national
securities exchange or another similar regulatory body including disclosing such information
in any clinical trial database maintained by or on behalf of a Party. Further, the
restrictions imposed on each Party under this Section 3.1(f) are not intended, and will not
be construed, to prohibit a Party from identifying the other Party in its internal business
communications, provided that any Confidential Information in such communications remains
subject to this Section 3.1(f).

     (g) Remedies. The Parties acknowledge and agree that the restrictions set
forth in this Section 3.1 are reasonable and necessary to protect the legitimate
interests of the Parties and that neither Party would have entered into this Agreement in
the absence of such restrictions, and that any breach or threatened breach of any provision
of this Section 3.1 will result in irreparable injury to the other Party for which
there will be no adequate remedy at law. Notwithstanding the arbitration provisions set
forth in Section 9.1(c), in the event of a breach or threatened breach of any provision of
Section 3.1 by a Party, the other Party will be authorized and entitled to obtain
from any court of competent jurisdiction injunctive relief, whether preliminary or
permanent, specific performance and an equitable accounting of all earnings, profits and
other benefits arising from such breach, which rights will be cumulative and in addition to
any other rights or remedies to which such Party may be entitled in law or equity. The
breaching Party

7

 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

agrees to waive any requirement that the non-breaching Party (i) post a bond or other
security as a condition for obtaining any such relief and (ii) show irreparable harm,
balancing of harms, consideration of the public interest or inadequacy of monetary damages
as a remedy. Nothing in this Section 3.1(g) is intended, or will be construed, to limit the
Parties’ rights to equitable relief or any other remedy for a breach of any provision of
this Agreement.

          Section 3.2 Compliance with Law. Each Party hereby covenants and agrees to comply with all
Applicable Laws applicable to its activities connected with the development of the Influenza
Vaccine. Without limiting the generality of the foregoing:

     (a) Patient Information . Each Party agrees to abide by all laws, rules,
regulations, and orders of all applicable supranational, national, federal, state,
provincial, and local governmental entities concerning the confidentiality or protection of
patient identifiable information and/or patients’ protected health information, as defined
by any other applicable legislation in the course of their performance under this Agreement.

     (b) Debarment. Each Party agrees that it will not use, in any capacity, in
connection with any of its obligations to be performed under this Agreement any individual
who has been debarred under the FD&C Act or the Generic Drug Enforcement Act or analogous
law.

          Section 3.3 Nonsolicitation of Employees. During the Term of this Agreement and for a period
of one year thereafter, each Party agrees that neither it nor any of its Affiliates will recruit,
solicit or induce any employee of the other Party that is involved in the activities conducted
pursuant to this Agreement to terminate his or her employment with such other Party and become
employed by or consult for such other Party, whether or not such employee is a full-time employee
of such other Party, and whether or not such employment is pursuant to a written agreement or is
at-will. For purposes of the foregoing, “recruit”, “solicit” or “induce” does not include (a)
circumstances where an employee of one Party initiates contact with the other Party or any of is
Affiliates with regard to possible employment, or (b) general solicitations of employment not
specifically targeted at employees of a Party or any of its Affiliates, including responses to
general advertisements. In addition, during the Term of this Agreement and for a period of one year
thereafter, neither Party may hire or employ any such employee of the other Party (including
personnel who were employees of such other Party within a period of one year or less from the date
of the proposed hiring or employment) without the prior written consent of such other Party, unless
such other Party had previously terminated the employment of such former employee.

ARTICLE 4

REGULATORY APPROVAL

          Section 4.1 Regulatory Matters.

8

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     (a) Responsibility For Regulatory Interactions. Regulatory strategy for the
Influenza Vaccine and all decision-making with respect thereto will be discussed by the
Parties and approved by Novavax. Avimex will use Commercially Reasonable Efforts to obtain
in a timely manner Regulatory Approvals in the name of Novavax with respect to the Influenza
Vaccine. Avimex will be primarily responsible for conducting all activities relating to
obtaining Regulatory Approvals in the Territory, including without limitation, preparing and
submitting Regulatory Submissions and attending meetings with Regulatory Authorities;
provided that Novavax may prepare filings or portions of the filings for review of Avimex if
Novavax so chooses and, in any event, Novavax will be included in the process of preparing
Regulatory Submissions and the contents of all Regulatory Submissions shall be subject to
Novavax approval, all as set forth in Section 4.1(b). Novavax will own all right,
title, and interest in, and shall be the entity named in, all Regulatory Submissions for the
Influenza Vaccine in the Territory. The costs incurred in carrying out the responsibilities
pursuant to this Section 4.1(a) will be born by Avimex.

     (b) Review of Regulatory Submissions.

     (i) Avimex will provide Novavax with advance copies of any substantive
Regulatory Submissions made by Avimex in the Territory reasonably in advance of
submission to a Regulatory Authority (and in any event no less than 10 days in
advance) and will provide Novavax a meaningful opportunity to comment or to make
suggestions, and Avimex will not unreasonably reject comments or suggestions from
Novavax. Avimex acknowledges that Novavax may share such Regulatory Submissions
with Third Party Licensees and seek input from same. Avimex will not submit any
Regulatory Submissions in any Territory unless Avimex has complied with this Section
4.1(b)(i) with respect to such Regulatory Submissions and has received written
consent of Novavax to such Regulatory Submissions.

     (ii) Novavax will keep Avimex reasonably informed as to the clinical
development of the Influenza Vaccine outside of the Territory. In the event that
any clinical trial results are not satisfactory and therefore would not support
Regulatory Approval in the Territory, then Avimex and Novavax will discuss and agree
whether clinical development should continue in the Territory and/or whether any
clinical development plans should be amended or terminated.

     (c) Trademarks. Subject to Novavax’s prior written approval, Avimex shall
develop, apply for, maintain and own one or more unique trademarks for the sale of Influenza
Vaccine by Avimex in the Territory (each a “Trademark”). Trademarks may be submitted with
the Regulatory Submissions as required by the applicable Regulatory Authority. Unless
otherwise agreed in writing, Trademarks shall be owned by Avimex and will remain Avimex’s
property at all times. No license, either express or implied, is granted to the Trademarks
by virtue of this Agreement to Novavax or any other third party.

9

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     (d) Regulatory Cooperation.

     (i) Novavax will either provide Avimex with reasonable assistance in compiling
Regulatory Submissions by providing any information, including but not limited to,
reports, summaries and overviews relating to development or manufacturing of the
Influenza Vaccine Product by Novavax or Novavax will compile such information to be
included in such Regulatory Submission.

     (ii) Novavax will use Commercially Reasonable Efforts under any arrangement
with Third Party Licensees to seek to have such Third Party Licensee provide to
Avimex the same information relating to development or manufacturing of the
Influenza Vaccine by the Third Party Licensee or its Affiliates as that described in
Section 4.1(d)(i), provided, however, that Novavax will have no
liability to Avimex for any failure to cause such Third Party to provide Avimex with
such information, so long as Novavax has used the reasonable efforts described
above.

     (iii) Avimex will keep Novavax reasonably informed regarding the status and
progress of development activity, including without limitation, providing such
Novavax with: (i) advance notice of all meetings scheduled with a Regulatory
Authority (including notice within 24 hours of a request for a meeting received from
a Regulatory Authority) related to the Influenza Vaccine; (ii) a copy of all
substantive written correspondence from a Regulatory Authority involving a
Regulatory Submission; and (iii) notice of all oral substantive correspondence from
a Regulatory Authority involving a Regulatory Submission. Avimex will provide
Novavax with an agenda and an invitation to attend substantive meetings with a
Regulatory Authority involving a Regulatory Submission. Furthermore, the Parties
will agree in advance on all substantive written communications with and, to the
extent permitted by Applicable Law, will both have the right to participate in all
meetings and oral communications with Regulatory Authorities. Avimex acknowledges
that Novavax may share such written communications, notices and agendas with Third
Party Licensees and seek input from same.

     (e) Clinical Trial Data. All clinical trial data being developed during the
Evaluation and any other clinical trial data being developed by or on behalf of Novavax from
the Influenza Vaccine, shall be maintained by a clinical resource organization or
statistical analyst chosen by Novavax (and reasonably acceptable to Avimex) (the “Data
CRO”). The Data CRO may merge all data into one master database as may be appropriate.
Avimex will have free access to all data held by the Data CRO resulting from clinical trials
conducted by Avimex under this Agreement. Novavax shall provide Avimex, within a reasonable
amount of time after any Avimex request, with access to clinical trial data developed by or
on behalf of Novavax related to the Influenza Vaccine. The use of the clinical trial data
generated during the Evaluation is set forth in Section 5.3.

10

 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     (f) Adverse Events. Within 60 days after the Effective Date, the Parties will
enter into a pharmacovigilance agreement, which upon such execution will be attached as
Exhibit A hereto and hereby incorporated into this Agreement by reference (the
“Pharmacovigilance Agreement”). The Parties will comply with the provisions of such
agreement. The Parties acknowledge and agree that Novavax maintains and will be the
recognized holder of a global safety database for adverse event reports related to the
Influenza Vaccine received by either Party. Novavax will cooperate with Avimex to the
extent Avimex requests access to such global safety database. Except as otherwise provided
in the Pharmacovigilance Agreement or as agreed to by the Parties, Novavax, or its designee,
will be responsible for responding to all safety inquiries regarding the Influenza Vaccine.

ARTICLE 5

OPTION

          Section 5.1 Grant of Option. Novavax hereby grants, on the terms and conditions hereof, an
irrevocable right and option to Avimex during the Term of this Agreement (the “Option”) to
enter into the non-exclusive Distribution Agreement in the form attached hereto as Exhibit
A (the “Distribution Agreement”).

          Section 5.2 Exercise of Option.

     (a) Voluntary Exercise of Option. So long as Avimex is in compliance with the
terms of this Agreement, Avimex shall have the right, in its sole and absolute discretion,
to exercise the Option at any time during the Term of this Agreement by sending a written
notice to Novavax, indicating a final decision to exercise the Option (“Positive
Decision Notice” or the “Option Exercise”).

     (b) Immediate Decision on Exercise of Option Upon Regulatory Approval. Within
7 calendar days of receipt of Regulatory Approval, if received during the Term, Avimex shall
notify Novavax in writing whether Avimex is exercising the Option at that time. If Avimex
notifies Novavax in writing that it is not exercising the Option at that time, or if Avimex
does not provide any written notice to Novavax within the 7 day period, then Novavax may
enter into arrangements with one or more third parties to sell Influenza Vaccine in the
Territory, using the clinical trial data as described in Section 5.3, [* * *].

          Section 5.3 Effect of Option Exercise or Option Termination Unexercised; Use of Clinical Trial
Data.

     (a) If the Option is exercised, and during the term of the Distribution Agreement, (i)
the results (including all data) of the clinical trials conducted in the Evaluation may be
used in the Territory exclusively by Avimex; and Novavax may use such results in any
Regulatory Submission with any governmental or health authorities in

11

 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

any country or with any international organization anywhere in the world, except in the
Territory; provided, however, if submission of the results to a regulatory authority is
required by Law, regulation or that Regulatory Authority (as reasonably determined by the
parties together when not clear), then Novavax may submit such results, and (ii) Novavax
will not authorize any Third Party to distribute Influenza Vaccine in the Territory under
the sanitary registration obtained in the name of Novavax under this Agreement with the
assistance of Avimex; provided that Novavax may authorize and cooperate with a Third Party
in seeking a separate sanitary registration for selling Influenza Vaccine in the Territory
as long as such application does not make use of the results as provided in (i).

     (b) If Avimex does not exercise the Option during the 7 day period set forth in Section
5.2(b), or fails to provide any notice in such 7 day period, the Option terminates
unexercised under Section 5.5, this Agreement is terminated by Novavax under Sections
7.2(a), (b) or (c) or by Avimex under Section 7.2(d), or the Distribution Agreement
terminates at the election of Avimex or due to an uncured breach of Avimex, Novavax may, or
may authorize Third Parties to, (i) use the results (including all data) of the clinical
trials conducted in the Evaluation anywhere in the world without exception and/or (ii)
distribute and sell Influenza Vaccine in the Territory under the sanitary registration
obtained in the name of Novavax under this Agreement with the assistance of Avimex.

          Section 5.4 Execution of Distribution Agreement. The parties agree to execute the
Distribution Agreement in the form attached hereto as Exhibit A upon the next business day
following the date on which the option is exercised exercised under Section 5.2.

          Section 5.5 Termination of Option; Potential Payment by Novavax.

     (a) The Option shall terminate, if not yet exercised, upon expiration of the Term or as
provided in Article 7 upon early termination of this Agreement under Article 7.

     (b) The Option shall terminate if Novavax desires to submit the Regulatory Submissions
to seek Regulatory Approval and Avimex declines to cooperate or participate in such
submission.

     (c) If (i) the Option terminates under Section 5.5(b), or Avimex does not exercise the
Option during the 7 day period set forth in Section 5.2(b), or fails to provide any notice
in such 7 day period, and (ii) Novavax enters into a distribution arrangement with another
company based in Mexico, and (iii) such distributor sells at least [* * *] doses of
Influenza Vaccine in Mexico, then Novavax shall pay to Avimex [* * *].

ARTICLE 6

RIGHT OF FIRST NEGOTIATION

12

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

          Section 6.1 Grant of Right of Negotiation. Subject to the commitment to enter into a
Collaboration and License Agreement between Novavax and Laboratories Farmaceuticos Rovi, S.A.,
based on the executed Head of Terms dated June 29, 2009, a redacted copy of which has been provided
to Avimex, and further subject to exercise of the Option and Regulatory Approval, Novavax hereby
agrees to negotiate, in good faith and on a non-exclusive basis, with Avimex for certain
non-exclusive distribution rights to (i) Novavax’s seasonal human influenza vaccine (“Seasonal
Vaccine”) in the Territory and (ii) the Influenza Vaccine and Seasonal Vaccine in the Latin
American countries that are listed on Exhibit C. Such negotiations shall commence within
three (3) months of the Option Exercise and continue for no more than thirty (30) days.

ARTICLE 7

TERM AND TERMINATION

          Section 7.1 Term. The term of this Agreement will commence on the Effective Date and, unless
earlier terminated as provided in this Article 7, will continue in full force and effect until
December 31, 2009 (the “Term”), unless the Option is exercised or deemed exercised, in
which case, the Term ends December 31, 2010.

          Section 7.2 Termination for Cause.

     (a) Termination for Material Breach. This Agreement may be terminated effective
immediately by written notice by a Party at any time during the Term if the other Party
materially breaches this Agreement, which breach remains uncured for 30 days measured from
the date written notice of such breach is given to the breaching Party. Such notice must
specify the nature of the breach and demand its cure; provided, however, that if such breach
is not capable of being cured within the stated period and the breaching Party uses
Commercially Reasonable Efforts to cure such breach during such period and presents a
mutually agreeable remediation plan for such breach, this Agreement will not terminate and
the cure period will be extended for such period provided in the remediation plan as long as
the breaching party continues to use Commercially Reasonable Efforts to pursue the cure as
provided in such remediation plan. Notwithstanding anything to the contrary set forth in
this Agreement, but subject to the limitations set forth in Section 8.6, termination will
not be deemed to relieve a defaulting Party from any liability arising from such default.

     (b) Violation of Law. This Agreement may be terminated by Novavax on giving 15
days’ written notice to Avimex, which will be effective on the expiration date of such 15
day period in the event that the Avimex or any of its Affiliates are convicted of a felony
for violating, or a final, non-appealable order is issued by a court of competent
jurisdiction finding that Avimex or any of its Affiliates violated, any Applicable Laws, the
Federal Foreign Corrupt Practices Act (or analogous law) or any securities laws or
regulations (collectively, the “Relevant Laws”), which are of such a nature that
such violation of such Relevant Laws would prevent or substantially diminish

13

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

either Party from performing or having the ability to perform its obligations pursuant
to this Agreement. Such notice of termination must be given within 15 days of Novavax
becoming aware of the circumstances described in this Section 7.2(b).

     (c) Bankruptcy. This Agreement may be terminated by written notice by either
Party at any time during the Term of this Agreement if the other Party will file in any
court or agency, pursuant to any statute or regulation of any state or country, a petition
in bankruptcy or insolvency or for reorganization or for an arrangement or for the
appointment of a receiver or trustee of that Party or of its assets, or if the other Party
proposes a written agreement of composition or extension of its debts, or if the other Party
will be served with an involuntary petition against it, filed in any insolvency proceeding,
and such petition is not dismissed within 60 days after the filing thereof, or if the other
Party proposes or is a Party to any dissolution or liquidation, or if the other Party makes
an assignment for the benefit of its creditors.

     (d) Termination for Convenience. Prior to its expiration, this Agreement may be
terminated in its entirety at any time by Avimex effective upon at least 30 days prior
written notice to Novavax for any reason. If Avimex terminates under this Section 7.2(d),
Avimex will provide all assistance reasonably requested by Novavax for at least 90 days
after the effective date of such termination to provide such assistance as may be reasonably
useful or necessary for Novavax to continue with the development and testing of the
Influenza Vaccine; provided that Novavax is responsible for expenses after termination.
Notwithstanding the foregoing sentence, Avimex will not be required to undertake any
development activities after providing notice of termination under this Section 7.2(d) for a
material safety issue but will provide assistance in identifying, further characterizing and
fully documenting such issue.

          Section 7.3 Effects of Termination.

     (a) Effects of Termination by Novavax. If this Agreement is terminated by
Novavax under Section 7.2(a), Section 7.2(b) or Section 7.2(c), or if Avimex terminates
under Section 7.2(d), then the following provisions will be effective upon such termination:

     (i) Avimex will furnish Novavax with reasonable cooperation to assure a smooth
transition of any clinical or other studies in progress related to the Influenza
Vaccine which Novavax determines to continue in compliance with Applicable Laws and
ethical guidelines applicable to the transfer or termination of any such studies;
provided that Novavax is responsible for expenses after termination. In addition,
Avimex will transfer to Novavax all data and information related to the Influenza
Vaccine generated or held by or on behalf of Avimex and will return all Novavax
Confidential Information to Novavax;

14

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     (ii) Until termination is effective, Avimex will continue to perform its
obligations hereunder, except with respect to activities that Novavax elects to
discontinue; and

     (iii) The Option shall terminate.

     (b) Effects of Termination by Avimex. If this Agreement is terminated by
Avimex pursuant to Section 7.2(a), Section 7.2(b) or Section 7.2(c), then until termination
is effective, Novavax will continue to perform its obligations hereunder, except with
respect to activities that Avimex elects to discontinue.

          Section 7.4 Survival of Certain Obligations. Expiration or termination of this Agreement
will not relieve the Parties of any obligation accruing before such expiration or termination. The
provisions of this Agreement that must, by their nature, survive expiration or termination of this
Agreement to give effect to their intent, will so survive, including without limitation Article 3,
Article 7, Article 8, or Article 9. Any expiration or early termination of this Agreement will be
without prejudice to the rights of either Party against the other accrued or accruing under this
Agreement before termination.

ARTICLE 8

PRODUCT LIABILITY, INDEMNIFICATION, AND INSURANCE

          Section 8.1 Indemnification by Novavax. Novavax will indemnify, defend and hold harmless
Avimex, its Affiliates, and each of its and their respective employees, officers, directors and
agents (each, an “Avimex Indemnified Party”) from and against any and all losses, damages,
liabilities, settlements, penalties, fines, and expenses (including, without limitation, reasonable
attorneys’ fees and expenses) (collectively, “Liability”) that the Avimex Indemnified Party
may be required to pay to one or more Third Parties to the extent resulting from or arising out of:

     (a) any Novavax representation or warranty set forth in this Agreement being untrue in
any material respect when made or any material breach by Novavax of any of its covenants or
obligations hereunder;

     (b) gross negligence or willful misconduct of Novavax; or

     (c) except, in each case, to the extent caused by the gross negligence or willful
misconduct of Avimex or any Avimex Indemnified Party, or by breach of this Agreement by
Avimex.

          Section 8.2 Indemnification by Avimex. Avimex will indemnify, defend and hold harmless
Novavax, its Affiliates, Sublicensees, distributors and each of its and their respective employees,
officers, directors and agents (each, a “Novavax Indemnified Party”) from

15

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

and against any and all Liabilities that the Novavax Indemnified Party may be required to pay
to one or more Third Parties to the extent resulting from or arising out of:

     (a) any Avimex representation or warranty set forth in this Agreement being untrue in
any material respect when made or a material breach by Avimex of any of its covenants or
obligations hereunder;

     (b) gross negligence or willful misconduct of Avimex; or

     (c) except in each case, to the extent caused by the gross negligence or willful
misconduct of Novavax or any Novavax Indemnified Party, or by breach of this Agreement by
Novavax.

          Section 8.3 Product Liability Claims. Notwithstanding anything to the contrary contained in
Article 8 of this Agreement, the Parties intend for the customer(s) of all Product to provide
indemnification to Avimex and Novavax for any product liability claim that may arise from the sale
or use of Product. Avimex shall use its best efforts to obtain covenants of indemnification for
all such product liability claims, but shall not be responsible for product liability claims by
virtue of its inability to obtain such indemnification despite its best efforts.

          Section 8.4 Procedure. Each Party will notify the other in the event it becomes aware of a
claim for which indemnification may be sought hereunder or for which Liability is shared pursuant
to this Article 8. In case any proceeding (including any governmental investigation) is instituted
involving any Party in respect of which indemnity may be sought pursuant to this Article 8, such
Party (the “Indemnified Party”) will promptly notify the other Party (the “Indemnifying
Party”) in writing and the Indemnifying Party and Indemnified Party will meet to discuss how to
respond to any claims that are the subject matter of such proceeding. The Indemnifying Party, upon
request of the Indemnified Party, will retain counsel reasonably satisfactory to the Indemnified
Party to represent the Indemnified Party and will pay the fees and expenses of such counsel related
to such proceeding. In any such proceeding, the Indemnified Party will have the right to retain
its own counsel, but the fees and expenses of such counsel will be at the expense of the
Indemnified Party unless (i) the Indemnifying Party and the Indemnified Party will have mutually
agreed to the retention of such counsel and payment of fees and expenses or (ii) the named parties
to any such proceeding (including any impleaded parties) include both the Indemnifying Party and
the Indemnified Party and representation of both Parties by the same counsel would be inappropriate
due to actual or potential differing interests between them. All such fees and expenses incurred
pursuant to Section 8.1 or Section 8.2 will be reimbursed as they are incurred. The Indemnifying
Party will not be liable for any settlement of any proceeding unless effected with its written
consent. The Indemnifying Party will not, without the written consent of the Indemnified Party,
effect any settlement of any pending or threatened proceeding in respect of which the Indemnified
Party is, or arising out of the same set of facts could have been, a party and indemnity could have
been sought hereunder by the Indemnified Party, unless such settlement includes an unconditional
release of the Indemnified Party from all liability on claims to which the indemnity relates that
are the subject matter of such proceeding.

16

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

          Section 8.5 Insurance. Each Party shall obtain and maintain, during the Term of this
Agreement, commercial general liability insurance, including but not limited to products liability
and clinical insurance, with reputable and financially secure insurance carriers to cover its
indemnification obligations under Section 8.1 or Section 8.2, as applicable, or self-insurance,
with limits of not less than 5 million U.S. dollars per occurrence and 10 million U.S. dollars in
the aggregate. Each Party shall list the other Party as an additional insured party on the
insurance policies described in this Section 8.5.

          Section 8.6 Liability Limitations. NOTWITHSTANDING THE FOREGOING, IN NO EVENT WILL EITHER
PARTY BE LIABLE TO THE OTHER FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE, OR
EXEMPLARY DAMAGES UNDER THIS AGREEMENT, EXCEPT TO THE EXTENT THE DAMAGES RESULT FROM A PARTY’S
WILLFUL MISCONDUCT OR ARISE FROM A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS Article 8.

ARTICLE 9

MISCELLANEOUS.

          Section 9.1 Governing Law; Jurisdiction; Dispute Resolution.

     (a) Governing Law. The interpretation and construction of this Agreement will
be governed by the laws of the State of Maryland and the United States of America, excluding
any conflicts or choice of law rule or principle that might otherwise refer construction or
interpretation of this Agreement to the substantive law of another jurisdiction.

     (b) Dispute Resolution. In the event of a dispute arising out of or relating to
this Agreement, either Party will provide written notice of the dispute to the other, in
which event the dispute will be referred to the executive officers designated below or their
successors, for attempted resolution by good faith negotiations within 15 days after such
notice is received. The initial designated officers (“Initial Officers”) are initially as
follows:

	 	 	 
	For Novavax:

	 	Its Chief Executive Officer
	For Avimex:

	 	Its General Director

          If the Initial Officers are unable to resolve the dispute within 10 days, the matter shall be
referred to the following:

	 	 	 
	For Novavax:

	 	Its Chairman of the Board
	For Avimex:

	 	Its Chairman of the Board

17

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

In the event the Chairmen of the Boards do not resolve such dispute within 5 days of the dispute
being elevated to their review, either Party may, after the expiration of the 15 day period from
receipt of the notice, seek to resolve the dispute through arbitration in accordance with Section
9.1(c).

          (c) Arbitration.

     (i) Arbitration Claims. Any claim, dispute, or controversy of whatever
nature arising between the Parties out of or relating to this Agreement that is not
resolved under Section 9.1(b) within the required 15 day time period, including
without limitation, any action or claim based on tort, contract, or statute
(including any claims of breach or violation of statutory or common law protections
from discrimination, harassment and hostile working environment), or concerning the
interpretation, effect, termination, validity, performance and/or breach of this
Agreement (“Arbitration Claim”), will be resolved by final and
binding arbitration before a single expert with relevant industry experience
selected by the Parties or, if the Parties cannot agree within ten (10) days, a
panel of three experts with relevant industry experience (each, an
“Arbitrator”). The panel of three Arbitrators shall be appointed in
accordance with the Rules of Arbitration of the International Chamber of Commerce.
The Arbitration will be administered under the Rules of Arbitration of the
International Chamber of Commerce (the “Administrator”). The arbitration
will be held in Mexico City, Mexico and conducted in English. The Arbitrators will
be instructed by the Parties to complete the arbitration within 60 days after
selection of the final Arbitrator.

     (ii) Arbitrators’ Award. The Arbitrators will, within 15 calendar days
after the conclusion of the arbitration hearing, issue a written award and statement
of decision describing the essential findings and conclusions on which the award is
based, including the calculation of any damages awarded. The decision or award
rendered by the Arbitrators will be final and non-appealable, and judgment may be
entered upon it in accordance with applicable law in any court of competent
jurisdiction. The Arbitrators will be authorized to award compensatory damages, but
will NOT be authorized (i) to award non-economic damages, such as for emotional
distress, pain and suffering or loss of consortium, (ii) to award punitive damages,
or (iii) to reform, modify or materially change this Agreement or any other
agreements contemplated hereunder; provided, however, that the
damage limitations described in parts (i) and (ii) of this sentence will not
apply if such damages are statutorily imposed.

     (iii) Costs. Each Party will bear its own attorney’s fees, costs, and
disbursements arising out of the arbitration and the costs of the arbitrator
selected by it, and will pay an equal share of the fees and costs of the third
arbitrator; provided, however, the Arbitrators will be authorized to
determine whether a party is the prevailing party, and if so, to award to that
prevailing party

18

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

reimbursement for its reasonable attorneys’ fees, costs and disbursements
(including, for example, expert witness fees and expenses, photocopy charges, travel
expenses, etc.), and/or the fees and costs of the Administrator and the Arbitrators.

     (iv) Compliance with this Agreement. Unless the Parties otherwise
agree in writing, during the period of time that any arbitration proceeding is
pending under this Agreement, the Parties will continue to comply with all those
terms and provisions of this Agreement that are not the subject of the pending
arbitration proceeding.

     (v) Injunctive or Other Equity Relief. Nothing contained in this
Agreement will deny any Party the right to seek injunctive or other equitable relief
from a court of competent jurisdiction in the context of a bona fide emergency or
prospective irreparable harm, and such an action may be filed and maintained
notwithstanding any ongoing arbitration proceeding.

          Section 9.2 Definitions. Capitalized terms not defined herein shall have the meaning set
forth below:

     (a) “Affiliate” means, with respect to a Person, any Person that controls, is
controlled by, or is under common control with such first Person. For purposes of this
definition only, “control” means (a) to possess, directly or indirectly, the power to direct
the management or policies of a Person, whether through ownership of voting securities or by
contract relating to voting rights or corporate governance, or (b) to own, directly or
indirectly, more than 50% of the outstanding voting securities or other ownership interests
of such Person.

     (b) “Applicable Law” means all applicable statutes, ordinances, regulations,
rules, or orders of any kind whatsoever of any Regulatory Authority, as amended from time to
time in the Territory, and, if applicable, under the laws of the United States.

     (c) “Change of Control” means any of the following: (i) the sale or disposition
of all or substantially all of the assets of a Party to a Third Party, (ii) the acquisition
by a Third Party or any group of Persons acting in concert, other than an employee benefit
plan (or related trust) sponsored or maintained by a Party or any of its Affiliates, of more
than 50% of such Party’s outstanding shares of voting capital stock (e.g., capital stock
entitled to vote generally for the election of directors), (iii) the appointment or election
to the board of directors of a Party of members constituting a majority of such board who
were not appointed, approved or recommended for election by the board of directors as
constituted immediately prior to the appointment or election of such majority, or (iv) the
merger or consolidation of a Party with or into another corporation or entity, other than,
in the case of (ii) or (iii), an acquisition or a merger or consolidation of a Party in
which holders of shares of such Party’s voting capital stock immediately prior to the
acquisition, merger or consolidation have at least 50% of the ownership of voting capital
stock of the

19

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

acquiring Third Party or the surviving entity in such merger or consolidation, as the case
may be, immediately after the merger or consolidation. Notwithstanding the foregoing, a
Change of Control will not be deemed to occur on account of the acquisition of securities of
a Party by an institutional investor, or Affiliate thereof, that acquires a Party’s
securities in a transaction or series of related transactions as a passive investment which
does not affect the management of such Party, or a sale of assets, merger or other
transaction effected exclusively for the purpose of changing the corporate domicile of a
Party.

     (d) “Commercially Reasonable Efforts” means those efforts and resources
normally used by a Third Party similarly situated to a Party hereunder for a product or
compound owned by such Third Party or to which such Third Party has rights of the type such
Party has hereunder, taking into account, without limitation, issues of safety and efficacy,
product profile, the proprietary position of the product or compound, the regulatory
environment and status of the compound, and other relevant scientific factors, market
conditions then prevailing, including the competitive environment, profitability, the extent
of market exclusivity, the cost to develop the compound or product, health economic claims,
and other similar factors reasonably determined by the Third Party to be relevant. Without
limiting the foregoing, Commercially Reasonable Efforts as it applies to the development the
Influenza Vaccine hereunder means adherence to the activities and time lines (to the extent
adherence to such activities and time lines is controllable by the Party responsible for
performing such activities) set forth in the protocols, as may be amended from time to time
based on the results of studies conducted with the Materials, as may be amended from time to
time, and regulatory factors.

     (e) “Confidential Information” means, with respect to a Party, all information
(and all tangible and intangible embodiments thereof), which is Controlled by such Party, is
disclosed by such Party to the other Party pursuant to this Agreement, and is designated as
confidential in writing by the disclosing Party whether by letter or by use of an
appropriate stamp or legend, prior to, at the time or promptly after any such information is
disclosed by the disclosing Party to the other Party. In addition, any information which is
orally, electronically or visually disclosed by a Party, or is disclosed in writing without
an appropriate letter, stamp or legend, will constitute Confidential Information if the
disclosing Party, within 30 days after such disclosure, delivers to the receiving Party a
written document or documents describing the information disclosed and referencing the place
and date of such oral, visual, electronic or written disclosure and the names of the
Person(s) to whom such disclosure was made.

     (f) “Control” or “Controlled” means, with respect to any intellectual
property right of a Party, that the Party or its Affiliate owns or has a license to such
intellectual property right and has the ability to grant access, a license, or a sublicense
to such intellectual property right to the other Party as provided in this Agreement without
violating an agreement with or other rights of any Third Party.

20

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     (g) “Person” means any individual, corporation, company, limited liability
company, partnership, limited liability partnership, trust, estate, proprietorship, joint
venture, association, organization, or entity.

     (h) “Production Costs” means the fully loaded cost of all raw materials,
consumables and supplies, labor, and production time.

     (i) “Regulatory Approval” means the approval and market authorization of a
Regulatory Authority in a country necessary to develop, manufacture, or commercialize,
including pricing and reimbursement approval where required, the Influenza Vaccine in the
Territory.

     (j) “Regulatory Authority” means any international (e.g., EMEA), national,
regional, state, or local regulatory agency, department, bureau, commission, council, or
other governmental entity in the Territory involved in the granting of Regulatory Approval
for the Influenza Vaccine in the Territory.

     (k) “Regulatory Submission” means applications for obtaining Regulatory
Approval and registration, notification, and other submissions made to or with a Regulatory
Authority that are necessary or reasonably desirable to develop, manufacture, or
commercialize the Influenza Vaccine in the Territory, whether obtained before or after
Regulatory Approval in the Territory. Regulatory Submissions include, without
limitation, investigative new drug applications and NDAs, and amendments and supplements to
any of the foregoing and their foreign counterparts, applications for pricing and
reimbursement approvals, and all proposed labels, labeling, package inserts, monographs, and
packaging for the Influenza Vaccine in the Territory.

     (l) “Third Party” means any Person other than Novavax, Avimex and their
respective Affiliates.

     (m) “Third Party Licensee” means a Third Party to whom Novavax has licensed any
rights to the Influenza Vaccine in any country outside the Territory.

          Section 9.3 Force Majeure. No liability will result from, and no right to terminate will
arise, in whole or in part, based upon any delay in performance or non-performance, in whole or in
part, by either of the Parties to this Agreement to the extent that such delay or non-performance
is caused by an event of Force Majeure. “Force Majeure” means an event that is beyond the
reasonable control of a non-performing Party (the “Force Majeure Party”), including an act
of God, act of the other Party, war, riot, civil commotion, terrorist act, malicious damage,
epidemic, quarantine, fire, flood, storm, natural disaster or compliance with any law or
governmental order, rule, regulation or direction, whether or not it is later held to be invalid or
inapplicable. The Force Majeure Party will within ten days of the occurrence of the Force Majeure
event, give written notice to the other Party stating the nature of the Force Majeure event, its
anticipated duration and any action being taken to avoid or minimize its effect. Any suspension of
performance will be of no greater scope and of no longer duration than is

21

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

reasonably required and the Force Majeure Party will use reasonable effort to remedy its inability
to perform; provided, however, if the suspension of performance continues or is anticipated to
continue for 30 days after the date of the occurrence, the unaffected Party will have the right but
not the obligation to perform on behalf of the Force Majeure Party for a period of such Force
Majeure and such additional period as may be reasonably required to assure a smooth and
uninterrupted transition of such activities. If such failure to perform would constitute a
material breach of this Agreement in the absence of such event of Force Majeure, and continues for
six months from the date of the occurrence and the Parties are not able to agree on appropriate
amendments within such period, such other Party will have the right, notwithstanding the first
sentence of this Section 9.3, to terminate this Agreement immediately by written notice to the
Force Majeure Party, in which case neither Party will have any liability to the other except for
those rights and liabilities that accrued prior to the date of termination and the consequences of
termination pursuant to Section 7.3(a) or Section 7.3(b), as applicable, as if such termination was
a termination as to which such consequences applied.

          Section 9.4 Additional Approvals. Avimex and Novavax will cooperate and use respectively all
reasonable efforts to make all other registrations, filings and applications, to give all notices
and to obtain as soon as practicable all governmental or other consents, transfers, approvals,
orders, qualifications authorizations, permits and waivers, if any, and to do all other things
necessary or desirable for the consummation of the transactions as contemplated hereby. Neither
Party will be required, however, to divest or out-license products or assets or materially change
its business if doing so is a condition of obtaining any governmental approvals of the transactions
contemplated by this Agreement.

          Section 9.5 Waiver and Non-Exclusion of Remedies. A Party’s failure to enforce, at any time
or for any period of time, any provision of this Agreement, or to exercise any right or remedy will
not constitute a waiver of that provision, right or remedy or prevent such Party from enforcing any
or all provisions of this Agreement and exercising any rights or remedies. To be effective any
waiver must be in writing. The rights and remedies provided in this Agreement are cumulative and
do not exclude any other right or remedy provided by law or otherwise available except as expressly
set forth in this Agreement.

          Section 9.6 Notices.

     (a) Notice Requirements. Any notice, request, demand, waiver, consent, approval
or other communication permitted or required under this Agreement must be in writing, must
refer specifically to this Agreement and will be deemed given only if delivered by hand or
sent by facsimile transmission (with transmission confirmed) or by internationally
recognized overnight delivery service that maintains records of delivery, addressed to the
Parties at their respective addresses specified in Section 9.6(b) or to such other address
as the Party to whom notice is to be given may have provided to the other Party in
accordance with this Section 9.6(a). Such Notice will be deemed to have been given as of
the date delivered by hand or transmitted by facsimile (with transmission confirmed) or on
the second business day (at the place of delivery) after deposit with an internationally
recognized overnight delivery service. This Section 9.6(a) is not

22

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

intended to govern the day-to-day business communications necessary between the Parties in
performing their obligations under the terms of this Agreement.

          (b) Address for Notice.

	 	 	 	 	 
	 	 	For Novavax:
	 
	 	 	Novavax, Inc.
	 	 	9920 Belward Campus Drive
	 	 	Rockville, MD 20850
	 	 	United States
	 

	 	Fax:
	 	240-268-2148
	 

	 	Attn:
	 	Senior Vice President, International

and Government Alliances
	 
	 	 	 	 
	 	 	With a copy to:
	 
	 	 	 	 
	 	 	Ballard Spahr LLP
	 	 	1735 Market Street, 51st Floor
	 	 	Philadelphia, PA 19103
	 

	 	Fax:
	 	215-864-9073
	 

	 	Attn:
	 	Jennifer Miller
	 
	 	 	 	 
	 	 	For Avimex:
	 
	 	 	 	 
	 	 	Laboratorio Avi-Mex S.A. de C.V.
	 	 	Maiz #18. Col. Granjas Esmeralda CP 09810
	 	 	Mexico City, Mexico
	 

	 	Fax:
	 	(55) 54450462
	 

	 	Attn:
	 	Bernardo Lozano Dubernard, General Director

          Section 9.7 Entire Agreement. This Agreement, constitutes the entire agreement between the
Parties with respect to the subject matter of this Agreement. This Agreement supersedes all prior
agreements, whether written or oral, with respect to the subject matter of this Agreement. Each
Party confirms that it is not relying on any representations, warranties or covenants of the other
Party except as specifically set out in this Agreement. Nothing in this Agreement is intended to
limit or exclude any liability for fraud. All Exhibits or Schedules referred to in this Agreement
are intended to be and are hereby specifically incorporated into and made a part of this Agreement.
In the event of any inconsistency between any such Exhibits or Schedules and this Agreement, the
terms of this Agreement will govern.

          Section 9.8 Amendment. Any amendment or modification of this Agreement must be in writing and
signed by authorized representatives of both Parties.

23

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

          Section 9.9 Assignment. Avimex may not assign its rights or delegate its obligations under
this Agreement, in whole or in part, by operation of law, via a Change in Control, or otherwise,
without the prior written consent of Novavax which can be given or withheld in Novavax’s
discretion. Novavax may not assign its rights or delegate its obligations under this Agreement, in
whole or in part, without the consent of Avimex, provided, however, that this Agreement may be
assigned by Novavax in connection with a Change in Control.

          Section 9.10 No Benefit to Others. The provisions of this Agreement are for the sole benefit
of the Parties and their successors and permitted assigns, and they will not be construed as
conferring any rights in any other persons except as otherwise expressly provided in this
Agreement.

          Section 9.11 Counterparts. This Agreement may be executed in any number of counterparts, each
of which will be deemed an original and all of which taken together will be deemed to constitute
one and the same instrument. An executed signature page of this Agreement delivered by facsimile
transmission will be as effective as an original executed signature page.

          Section 9.12 Severability. To the fullest extent permitted by applicable law, the Parties
waive any provision of law that would render any provision in this Agreement invalid, illegal or
unenforceable in any respect. If any provision of this Agreement is held to be invalid, illegal or
unenforceable, in any respect, then such provision will be given no effect by the Parties and will
not form part of this Agreement. To the fullest extent permitted by applicable law and if the
rights or obligations of any Party will not be materially and adversely affected, all other
provisions of this Agreement will remain in full force and effect and the Parties will use their
best efforts to negotiate a provision in replacement of the provision held invalid, illegal or
unenforceable that is consistent with applicable law and achieves, as nearly as possible, the
original intention of the Parties.

          Section 9.13 Further Assurance. Each Party will perform all further acts and things and
execute and deliver such further documents as may be necessary or as the other Party may reasonably
require to implement or give effect to this Agreement.

          Section 9.14 Publicity. It is understood that the Parties will issue a press release
announcing the execution of this Agreement in such form as the Parties mutually agree. The Parties
will consult with each other reasonably and in good faith with respect to the text and timing of
any subsequent press releases relating to this Agreement or the activity hereunder prior to the
issuance thereof, provided that a Party may not unreasonably withhold consent to such releases, and
that either Party may issue such press releases as it determines, based on advice of counsel, are
reasonably necessary to comply with laws or regulations or for appropriate market disclosure or
which are consistent with information disclosed in prior releases properly made hereunder.

          Section 9.15 Relationship of the Parties. The status of a Party under this Agreement will be
that of an independent contractor. Nothing contained in this Agreement will

24

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

be construed as creating a partnership, joint venture, or agency relationship between the Parties
or, except as otherwise expressly provided in this Agreement, as granting either Party the
authority to bind or contract any obligation in the name of or on the account of the other Party or
to make any statements, representations, warranties, or commitments on behalf of the other Party.
All Persons employed by a Party or any of its Affiliates are employees of such Party or its
Affiliates and not of the other Party or such other Party’s Affiliates and all costs and
obligations incurred by reason of any such employment will be for the account and expense of such
Party or its Affiliates, as applicable.

25

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     IN WITNESS WHEREOF, duty authorized representatives of the Parties have duly executed this
Agreement to be effective as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	NOVAVAX, INC.	 	 	 	Laboratorio Avi-mex, S.A. de C.V.	 	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	By:	 	/s/ Rahul Singhvi	 	 	 	By:	 	/s/ Bernard Lozano	 	 
	 	 	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	Rahul Singhvi
	 	 	 	 	 	Name:
	 	Bernard Lozano	 	 
	 

	 	Title:
	 	President and CEO
	 	 	 	 	 	Title:
	 	General Director	 	 

26

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

Exhibit A

Form of Distribution Agreement

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

DISTRIBUTION AGREEMENT

     THIS DISTRIBUTION AGREEMENT (this “Agreement”) dated                      ___, 20__ (the
“Effective Date”), is entered into by and between Novavax, Inc., a corporation organized
under the laws of Delaware, United States (the “Supplier”), and Laboratorio Avi-Mex, S.A.
de C.V., a private company organized under the federal laws of Mexico (the “Distributor”).
Each of Supplier and Distributor may be collectively referred to as the “Parties” and each
individually as a “Party”.

WITNESSETH:

     WHEREAS, Supplier is a manufacturer of the Product (as defined herein), and desires that
Product be sold to customers in the Territory (as defined herein);

     WHEREAS, Supplier and Distributor are parties to that certain Materials Transfer Agreement
dated October 19, 2009 (the “Materials Transfer Agreement”), pursuant to which Distributor
was granted an option to enter into this Agreement, which option was exercised on                      ___, 20__;

     WHEREAS, Distributor desires to purchase Product for resale to its customers in the Territory
and to otherwise act as a sales representative for Product in the Territory; and

     WHEREAS, Supplier desires that Distributor act in such capacities in the Territory.

     NOW, THEREFORE, in consideration of the mutual covenants and conditions contained herein and
intending to be legally bound, the parties hereby agree as follows.

ARTICLE 1

DEFINITIONS

     Section 1.1 Definitions. As used in this Agreement, the following terms shall have
the meanings set forth below.

     “Affiliate” means any corporation, firm, partnership, or other entity, whether de jure
or de facto, that directly or indirectly controls, is controlled by or is under common control with
a party to this Agreement.

     “Change of Control” means any of the following: (i) the sale or disposition of all or
substantially all of the assets of a Party to a Third Party, (ii) the acquisition by a Third Party
or any group of Persons acting in concert, other than an employee benefit plan (or related trust)
sponsored or maintained by a Party or any of its Affiliates, of more than 50% of such Party’s
outstanding shares of voting capital stock (e.g., capital stock entitled to vote generally for the
election of directors), (iii) the appointment or election to the board of directors of a Party of
members constituting a majority of such board who were not appointed, approved or
recommended for election by the board of directors as constituted immediately prior to the

 

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

appointment or election of such majority, or (iv) the merger or consolidation of a Party with or
into another corporation or entity, other than, in the case of (ii) or (iii), an acquisition or a
merger or consolidation of a Party in which holders of shares of such Party’s voting capital stock
immediately prior to the acquisition, merger or consolidation have at least 50% of the ownership of
voting capital stock of the acquiring Third Party or the surviving entity in such merger or
consolidation, as the case may be, immediately after the merger or consolidation. Notwithstanding
the foregoing, a Change of Control will not be deemed to occur on account of the acquisition of
securities of a Party by an institutional investor, or Affiliate thereof, that acquires a Party’s
securities in a transaction or series of related transactions as a passive investment which does
not affect the management of such Party, or a sale of assets, merger or other transaction effected
exclusively for the purpose of changing the corporate domicile of a Party.

     [* * *]

     “Net Sales” means the gross amount invoiced for any sale of the Product by
Distributor, to a non-Affiliate in a bona fide arm’s length transaction, less the following
deductions, in each case to the extent specifically related to the Product and taken by the
Distributor or otherwise paid for or accrued by the Distributor in accordance with GAAP
(“Permitted Deductions”):

     (i) trade, cash, promotional and quantity discounts and wholesaler fees;

     (ii) taxes on sales (such as excise, sales or use taxes or value added taxes)
to the extent imposed upon and paid directly with respect to the sales price (and
excluding national, sales or local taxes based on income);

     (iii) freight, insurance, packing costs and other transportation charges to the
extent included in the invoice price to the buyer;

     (iv) amounts repaid or credits taken by reason of damaged goods, rejections,
defects, expired dating, recalls, returns or because of retroactive price
reductions; and

     (v) charge back payments and rebates granted to (a) managed healthcare
organizations, (b) federal, state and/or provincial and/or local governments or
other agencies, (c) purchasers and reimbursers, or (d) trade customers, including
wholesalers and chain and pharmacy buying groups.

     It is understood that accruals taken as a deduction against Net Sales will be periodically
reviewed by Supplier in accordance with GAAP and if any accrual is reversed by Distributor a
corresponding credit will be made to Net Sales in the period in which the reversal is made.

     “Product” means Novavax’s current monovalent intra-muscular H1N1 influenza vaccine
containing a virus like particle (VLP) consisting of [* * *]

A-2

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

as designated as pandemic by the World Health Organization
(WHO) Collaborating Centers for Reference and Research on Influenza located at the Centers for
Disease Control and Prevention (CDC) in Atlanta, Georgia.

     [* * *]

     “Regulatory Authority” means the Federal Commission for Protection Against Sanitary
Risks in Mexico.

     “Territory” means the country of Mexico.

     “Third Party” means any entity or person other than a party to this Agreement or an
Affiliate of either the Supplier or the Distributor.

     “Third Party Licensee” means a Third Party to whom Supplier has licensed any rights to
the Product in any country outside the Territory.

     Section 1.2 Additional Definitions. Each of the following definitions is set forth in
the section of this Agreement indicated below:

	 	 	 
	Administrator

	 	Section 9.1(c)(i)
	Agreement

	 	First Paragraph
	Arbitration Claim

	 	Section 9.1(c)(i)
	Arbitrator

	 	Section 9.1(c)(i)
	Authorized Recipients

	 	Section 12.1
	Confidential Information

	 	Section 12.1
	Delivered

	 	Section 5.1
	Delivery

	 	Section 5.1
	Disclosing Party

	 	Section 12.1
	Distributor

	 	First Paragraph
	Distributor Indemnified Party

	 	Section 8.1
	Effective Date

	 	First Paragraph
	Final Report

	 	Section 4.3(c)
	Force Majeure

	 	Section 14.3
	Force Majeure Party

	 	Section 14.3
	Indemnified Party

	 	Section 11.4
	Indemnifying Party

	 	Section 11.4
	Initial Officers

	 	Section 14.1(b)
	Initial Order

	 	Section 4.2
	JSC

	 	Section 6.1
	Liability

	 	Section 8.1
	Materials Transfer Agreement

	 	Recitals
	Order

	 	Section 3.1(c)
	Product Liability Claim

	 	Section 11.3
	Recall

	 	Section 9.3
	Receiving Party

	 	Section 12.1

A-3

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

	 	 	 
	Shipped Product

	 	Section 5.1
	Supplier

	 	First Paragraph
	Supplier Indemnified Party

	 	Section 11.2
	Term

	 	Section 13.1
	Transfer Price

	 	Section 4.3(a)

     Section 1.3 Construction. The parties have participated jointly in the negotiation
and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation
arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption
or burden of proof shall arise favoring or disfavoring either party by virtue of the authorship of
any of the provisions of this Agreement. Any reference to any federal, state, local, or foreign
statute or law shall be deemed also to refer to all rules and regulations promulgated thereunder,
unless the context requires otherwise. The word “including” in any form shall mean including
without limitation.

ARTICLE 2

APPOINTMENT AS DISTRIBUTOR

     Section 2.1 Distribution Rights. Supplier hereby grants Distributor the non-exclusive
right to purchase the Product described in Exhibit A attached hereto during the Term of
this Agreement from the Supplier and to sell or resell the Product to any customer located in the
Territory. The rights of the Distributor are subject to the terms and conditions of this
Agreement. No rights whatsoever are granted to distribute Product outside the Territory, whether
directly or indirectly through purchasers in the Territory for resale or other distribution outside
the Territory. Distributor hereby agrees to market, promote, sell, service and support the Product
in conformity with and subject to the terms and conditions of this Agreement and further agrees not
to sell or otherwise distribute Product to purchasers in the Territory for resale or other
distribution outside the Territory. Distributor agrees that nothing herein shall be deemed to
grant any right or license, express or implied, under any patents, know-how or other proprietary
rights or intellectual property owned or controlled by Supplier.

     Section 2.2 Consideration for Distribution Rights. As consideration for the rights
granted pursuant to Section 2.1, Distributor shall pay Supplier the following non-refundable,
non-creditable payments:

     (a) [* * *] within twenty (20) days of [* * *]; and

     (b) [* * *] within twenty (20) days of [* * *].

     Section 2.3 Nature of Relationship. The relationship established between Supplier and
Distributor by this Agreement is that of supplier and representative. Distributor is an
independent contractor under this Agreement and shall not have the right to assume or create any
obligation of any kind, either express or implied, on behalf of Supplier, except as expressly
provided for in this Agreement. Nothing in this Agreement shall be deemed to establish or

A-4

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

otherwise create a relationship of principal and agent, employer and employee, or otherwise between
Supplier and Distributor.

     Section 2.4 Right to Sell Other Product. During the Term, the Distributor will have
the right and discretion to sell, and enter into distribution agreements to resell, products of
Third Parties; provided, however, that Distributor may not distribute other pandemic influenza
vaccines for use in humans that are directly competitive with the Product unless specifically
agreed to in writing in advance by Supplier. Distributor shall avoid all circumstances and actions
that would place Distributor in a position of adverse interest or divided loyalty with respect to
its obligations under this Agreement.

ARTICLE 3

RESPONSIBILITIES

     Section 3.1 Responsibilities of Distributor. Distributor shall at all times during
the Term of this Agreement:

          (a) assume all market risk relating to Product in the Territory (being the risk the
Product does not sell in the Territory);

          (b) except as set forth in Supplier’s warranties, assume all risks relating to
inventory, including risk related to Product quality (but not with respect to product
recalls), order processing errors, mistakes in the communication of Product specifications,
customer credit, customer liability or other and related matters;

          (c) actively and diligently promote the sale of the Product by, among other things,
solicitation of inquiries and calls on customers and prospective customers to obtain
inquiries, and by rendering such services as may be required to present and sell the
Product;

          (d) maintain at all times a stock of Product at the warehouse location in Mexico City,
Mexico necessary to supply reasonable estimated demand by Distributor, and to maintain
delivery times not to exceed two (2) weeks to customers, with consideration given to normal
time delays outside the reasonable control of the Distributor. Such Product is to be stored
according to Supplier’s instructions and dispatched under the inventory principles of FIFO
(first in first out);

          (e) develop and implement a quality control process for Product handling in the
Territory;

          (f) cooperate with and represent Supplier in promotional efforts;

          (g) maintain records and summary reports regarding such communications with customers
and prospective customers, and shall provide such items to Supplier upon request of
Supplier;

A-5

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

          (h) furnish to Supplier such other reports and information relating to the purpose of
this Agreement (which includes but is not limited to sales activities, market prices,
Product and strategies of competitors, possible new Product, future customer needs, market
trends, and related matters) that may reasonably be requested from time to time by Supplier
or that Distributor shall become aware of during the Term of this Agreement;

          (i) deliver the Product in the packaging provided;

          (j) perform administrative support functions such as maintenance of accurate and
current customer records, order processing, customer credit review, customer invoicing, and
accounts receivable processing for all sales of the Product to customers in the Territory;

          (k) comply with all tax, including value-added taxes, import and export and custom
laws, rules and regulations in the Territory; and

          (l) immediately notify Supplier in writing of any claim or notice received that alleges
that the Product infringes any patent, trademark, copyright, trade secret, or similar law in
order to allow Supplier to defend such claims.

     Section 3.2 Responsibilities of Supplier. Supplier shall at all times during the Term
of this Agreement:

          (a) supply Product to Distributor in accordance with this Agreement;

          (b) provide to Distributor, without charge, such technical information materials
regarding the Product as Supplier deems reasonably necessary; and full information with
respect to all Product specification changes.

          (c) assume no market risk (risk that Product does not sell in the Territory); and

          (d) assume responsibility for all costs and risks related to the manufacture and sale
of Product not expressly assumed by Distributor under this Agreement.

     Section 3.3 Regulatory Information. Supplier accepts the responsibility to provide
the Distributor with complete information regarding limitations on the use of the Product.
Responsibilities of the parties with regard to obtaining and maintaining all governmental
approvals, except those related to customs and importation, necessary for the Distributor to
sell the Product in the Territory are set forth in the Materials Transfer Agreement.

A-6

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

ARTICLE 4

TERMS OF SALE OF PRODUCT

     Section 4.1 Purchase of Product. Distributor shall purchase all Product ordered from
Supplier pursuant to Section 4.2 and shall retain it in its own inventory at the warehouse in
Mexico City, Mexico. Distributor shall deliver such Product to its customers, and shall be
responsible for sending invoices to such customers and for collecting any purchase price or other
charges due therefor. Supplier shall not be responsible for, or incur any liability in respect to,
sales by Distributor to its end customers.

     Section 4.2 Orders; Minimum Initial Order. On the Effective Date, Distributor is
deemed to have ordered [* * *] doses of [* * *] mg of the Product (provided Supplier has the
capacity and yield levels to produce such amounts and subject to proration if the final dose of the
Product is greater or less than [* * *] mg per dose) (the “Initial Order”). Subject
to further agreement of the parties, Supplier may order, purchase and sell additional doses of
Product under the terms and conditions of this Agreement.

     Section 4.3 Payment Terms.

     (a) Prepayments. Distributor shall pay Supplier a 20% prepayment of the
Transfer Price of the Initial Order within ten (10) days of the Initial Order.

     (b) Transfer Price. Distributor shall pay to Supplier a “Transfer
Price” equal to [* * *] per dose for the first [* * *] doses of the Product delivered to
Supplier and [* * *] per dose for all other doses of the Product delivered to Supplier
within 30 days of delivery; provided that the Transfer Price shall be reduced for the first
[* * *] doses of Product delivered the amounts paid by Distributor to Supplier pursuant to
(x) Section 1.4(b) of the Materials Transfer Agreement and (y) Section 4.3(a) of this
Agreement.

     (c) Additional Purchase Price (Adjustment to Net Sales Percentage). Within
thirty (30) days of Distributor’s sale of all of the Product in the Initial Order,
Distributor shall submit to Supplier a comprehensive and detailed written report, with
back-up documentation as Supplier may reasonably request, detailing and documenting, all
purchases and sales of the Product, the Net Sales therefrom, and the relevant calculations
in accordance with the foregoing (the “Final Report”). The Final Report shall set
forth the additional purchase price to be paid by Distributor to Supplier, if any, which
shall be calculated as follows:

     (i) [* * *]% of Net Sales of sales of the first [* * *] doses of the Product
sold;

     (ii) Plus [* * *]% of Net Sales of sales of all other doses of the Product
sold;

A-7

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     (iii) Less an amount, if a positive number, equal to the product of (A) [* *
*]% of the amount that the average Net Sales price per dose sold exceeds [* * *] and
(B) the number of doses sold;

     (iv) Less the prepayment paid by Distributor to Supplier pursuant to Section
4.3(a));

     (v) Less the amounts paid by Distributor to Supplier pursuant to Section 1.4(b)
of the Materials Transfer Agreement; and

     (vi) Less the amount paid by Distributor to Supplier pursuant to Section
4.3(b).

     Section 4.4 Letter of Credit. On the date of execution of this Agreement, Distributor
will provide an irrevocable letter of credit, in form and substance and issued by a banking
institution reasonably acceptable to Supplier, in the amount of the aggregate of the PrePayment and
Transfer Price to be paid by Distributor for the Initial Order. Supplier shall be entitled to draw
on the Letter of Credit, with no action required on the part of Distributor, if Distributor fails
to make timely payment of the PrePayment or the Transfer Price.

     Section 4.5 Taxes. Any foreign, federal, state, county or local sales, use,
value-added or excise tax or similar charge, including customs and import duties, or other tax
assessment (other than that assessed against income), license fee (other than royalties owed to
Third Parties) or other charge lawfully assessed or charged on the sale or transportation of
Shipped Product sold pursuant to this Agreement after Delivery to Distributor shall be paid by
Distributor.

     Section 4.6 Currency. All purchase transactions between Supplier and Distributor
shall be denominated in, and all reports and calculations of payments shall be made in United
States Dollars.

ARTICLE 5

SHIPMENT AND DELIVERY

     Section 5.1 Shipment. Delivery shall occur for Product purchased from Supplier
(“Shipped Product”) [* * *] (“Delivery” or “Delivered”).

     Section 5.2 Delivery. For Delivery of Shipped Product, Supplier and Distributor will
agree to shipping instructions.

     Section 5.3 Export Licenses: Import Certificates; Customs and Regulatory Approvals.

          (a) Distributor’s Responsibilities. Distributor, at its cost, shall obtain all
authorizations required to import the Shipped Product into the Territory; and pay all
applicable freight, import and custom duties, taxes and fees.

A-8

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

          (b) Supplier’s Responsibilities. Supplier shall: (i) obtain any export license
required to export the Shipped Product to the Territory and obtain all required export
authorizations; and (ii) take all reasonable steps to cooperate with Distributor in
complying with any import, export or custom regulations applicable to the Shipped Product,
to the extent consistent with applicable law, including filling out necessary paperwork or
reports to obtain any applicable waiver, exemption or reduction of such duties in a timely
manner.

     Section 5.4 Title and Risk of Loss. Title to and risk of loss of Shipped Product
shall pass to Distributor at the place and time of Delivery. Any loss or damage to Shipped Product
prior to Delivery shall be at Supplier’s risk.

ARTICLE 6

JOINT STEERING COMMITTEE.

     Section 6.1 Overview. The Parties will establish a Joint Steering Committee
(“JSC”) that will be responsible for overseeing the marketing, pricing and distribution of
the Product in the Territory, and will serve as a forum for exchanging data, information, and
Development strategy(ies) regarding the Product. The Parties anticipate that the JSC will perform
the functions ascribed to it in this Section 6.1; provided, however, that the
functions and operations of the JSC may be altered from time to time during the Term by the mutual
agreement of the Parties to appropriately address ongoing requirements with respect to the
marketing and distribution of the Product.

     Section 6.2 Membership. The JSC will consist of three senior representatives from
each Party, including at least one executive level officer from each Party. Supplier and
Distributor will each designate a co-chair for the JSC. The co-chairs will be responsible for
calling meetings and setting the agenda (which will include a list of all participants expected at
a meeting) and circulating such agenda at least ten days prior to each meeting and distributing
minutes of the meetings within 30 days following such meeting (which minutes will be in the English
language), but will not otherwise have any greater power or authority than any other member of the
JSC. Each member must have expertise in regulatory matters, medical affairs, clinical research,
commercialization, marketing, distribution or such other expertise as appropriate to the activities
of the JSC. From time to time, the JSC may invite personnel of the Parties or other outside
consultants who are agreed upon by the Parties, in each case having commercial, marketing,
reimbursement or other expertise to participate in discussions of the JSC as appropriate to assist
in the activities of the JSC.

     Section 6.3 Responsibilities. The JSC’s responsibilities will include, among others:
(i) reviewing Distributor’s strategy for marketing and selling the Product in the Territory; (ii)
overseeing the implementation or any marketing or distribution strategy in the Territory (including
strategies related to reimbursement, advertising and promotion, brand integrity, sale and launch
sequence); (iii) overseeing the strategy and implementation of the branding of the Product in the
Territory, including the selection and maintenance of any trademarks to be used in connection with
the Product in the Territory (provided that Supplier approval is required for all

A-9

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

trademarks) and
(iv) establishing usage instructions for the trademarks. No license, either express or implied, is
granted to any trademarks between the parties by virtue of this Agreement. Any trademarks of the
parties shall remain each Party’s property at all times.

     Section 6.4 Meetings. During the Term, the JSC will meet at such frequency as will be
established by the Parties. Meetings of the JSC will alternate between the offices of the Parties
or their Affiliates, unless otherwise agreed upon by the members of the JSC, or may be held
telephonically or by video conference. All meetings of the JSC will be conducted in English.
Meetings of the JSC will be effective only if at least one representative of each Party is in
attendance or participating in the meeting. Members of the JSC may participate in and vote at
meetings by telephone. Each Party will be responsible for expenses incurred by its employees and
its members of the JSC in attending or otherwise participating in JSC meetings. Each Party will
use reasonable efforts to cause its representatives to attend the meetings of the JSC. If a
representative of a Party is unable to attend a meeting, such Party may designate an alternate with
equivalent experience and authority as such representative to attend such meeting in place of the
absent representative.

     Section 6.5 Minutes. The minutes of each JSC meeting must provide a description in
reasonable detail of the discussions held at the meeting and a list of any actions, decisions or
determinations approved by the JSC. Minutes of each JSC meeting will be approved or disapproved,
and revised as necessary, at the next meeting. Minutes will be kept in English.

     Section 6.6 Elevation and Dispute Resolution. Each Party’s representatives on the JSC
will collectively have one vote on all matters that are within the responsibility of such
committee. The members of each committee will use reasonable efforts to reach consensus on all
decisions. In the event that the members of the JSC are unable to agree on a particular issue,
such issue will be referred to Distributor’s Chief Executive Officer and Supplier’s Chief
Executive Officer. Subject to the remaining provisions of this Section 6.6, all matters relating
to the marketing and distribution of the Products must be determined by consensus of the Parties.
The Parties will from time to time identify a panel of mutually agreed consultants with expertise
in vaccine distribution to assist the JSC in the resolution of issues taking into consideration the
interests of each Party and, upon the request of either Party, such experts will be requested to
advise as to distribution issues where consensus cannot be reached, with the advice of such experts
not to be unreasonably rejected except with respect to any decision that requires consent of
Supplier (e.g., trademarks).

ARTICLE 7

REPORTS, RECORDS AND AUDIT

     Section 7.1 Reports. By the 5th day of each month, Distributor shall
deliver to Supplier a true and accurate report, giving a comprehensive and detailed written report,
with back-up documentation as Supplier may reasonably request, detailing and documenting, for the
preceding calendar month, all sales of the Product, the Net Sales therefrom, deductions applicable
to determine Net Sales thereof, a calculation of the amount due to Supplier for the relevant
period. Each report also will contain Distributor’s good faith, non-binding estimate of

A-10

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

total Net
Sales for all Products by Distributor for each of the next three calendar months beginning with the
calendar month in which such report is delivered.

     Section 7.2 Records; Audit. During the term of this Agreement and for three (3) years
thereafter, Distributor shall keep complete and accurate records of sales of Products and such
other matters as may affect the determination of any amount payable to Supplier hereunder in
sufficient detail to enable certified public accountants engaged by Supplier to determine any
amounts payable to Supplier under this Agreement. Distributor shall permit certified public
accountants engaged by Supplier, at Supplier’s expense (except as provided below), to examine, not
more than once in any six-month period, its books, ledgers, and records during regular business
hours for the purpose of and to the extent necessary to verify any report required under this
Agreement or the accuracy of any amount payable hereunder. Payment of any underpayment shall be
made as soon as practicable upon receipt of the report of the accountants. Should any examination
conducted by Supplier or its representatives pursuant to the provisions of this paragraph result in
an increase of more than 10% of any payment due Supplier hereunder, Distributor shall be obligated
to reimburse any out of pocket expenses incurred by Supplier with respect to such examination
within thirty (30) days after receipt of an invoice therefor from Supplier.

ARTICLE 8

WARRANTIES

     Section 8.1 Warranties Provided by Supplier. The warranties provided by Supplier to
Distributor with respect to the Product are:

          (a) Product Warranty. Supplier warrants that the Product sold by it is free from
defects in materials and workmanship and conform to the specifications as described in the
applicable package insert that accompany the Product. Supplier makes no other warranty,
expressed or implied, with respect to the Product, including any warranty of merchantability
or fitness for any particular purpose. Notification of any breach of warranty must be made
within 30 days after receipt as to shipment-related claims and within 90 days for all other
claims. No claim shall be honored if Distributor fails to notify Supplier within the period
specified.

          (b) Limitations of Liability. Supplier makes no express warranty, and excludes and
disclaims, to the extent permitted by applicable law, any and all implied warranties
including, without limitation, implied warranties in connection with the design, sale and
merchantability or fitness of the Product for any particular purpose or use, except for the
specific warranties related to the Product provided herein.

     Section 8.2 Right to Extend Warranties to Distributors and Customers.

          (a) Supplier extends to Distributor the warranties with respect to all Product sold to
Distributor pursuant to this Agreement, and specifically authorizes and consents to the
right of Distributor to pass on such warranty protection to its customers;

A-11

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

provided,
however, Supplier shall have no obligations with respect to Product warranties except those
obligations as set forth in Section 8.1.

          (b) Supplier shall take responsibility, as between Distributor and Supplier, for all
customer warranty claims properly honored by Distributor that falls under the terms of
Supplier’s warranties set forth above in Section 8.1. The parties will work together to
develop procedures and mechanisms, as necessary, to effectuate the foregoing.

     Section 8.3 Representations and Covenants of Distributor.

          (a) With respect to the Product, Distributor shall:

     (i) not make any representation, warranty, or guaranty in connection with the
Product other than as authorized by Supplier, unless Distributor agrees, in writing,
to assume full liability for such representation, warranty or guaranty;

     (ii) advise Supplier of any claim for damages or breach of warranty in respect
to the Product asserted by a customer purchasing such Product from Distributor and
shall cooperate with Supplier in the defense or handling of such claims; and

     (iii) promptly furnish Supplier with product samples and any related
information when a warranty claim is made by a customer.

          (b) Distributor represents and warrants to Supplier that, and Distributor covenants
that, none of Distributor or any of its Subsidiaries or any of their respective
representatives has or will corruptly (within the meaning of Applicable Law) or otherwise
illegally offered, paid, promised to pay, or authorized the payment of any money, or
offered, given, promised to give, or authorized the giving of anything of value to: (1) any
government or similar official for purposes of (A) (i) influencing any act or decision of
such official in his or her official capacity, (ii) inducing such official to do or omit to
do any act in violation of the lawful duty of such official, or (iii) securing any improper
advantage; or (B) inducing such official to use his or her influence with a
governmental entity or regulatory body to affect or influence any act or decision of
such governmental entity or regulatory body, in order to assist Distributor or any of its
Subsidiaries in obtaining or retaining business for or with, or directing business to, any
Person; (2) any political party or official thereof or any candidate for political office
for purposes of (A) (i) influencing any act or decision of such party, official, or
candidate in its or his or her official capacity, (ii) inducing such party, official, or
candidate to do or omit to do an act in violation of the lawful duty of such party,
official, or candidate, or (iii) securing any improper advantage; or (B) inducing such
party, official, or candidate to use its or his or her influence with a governmental entity
or regulatory body to affect or influence any act or decision of such governmental entity or
regulatory body in order to assist Distributor or any of its Subsidiaries in obtaining or
retaining business for or with, or directing business to, any Person; or (3) any Person,
while knowing that all or a

A-12

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

portion of such money or thing of value will be offered, given,
or promised, directly or indirectly, to any official, to any political party or official
thereof, or to any candidate for political office, for purposes of (A) (i) influencing any
act or decision of such official, political party, party official, or candidate in his or
her or its official capacity, (ii) inducing such official, political party, party official,
or candidate to do or omit to do any act in violation of the lawful duty of such official,
political party, party official, or candidate, or (iii) securing any improper advantage; or
(B) inducing such official, political party, party official, or candidate to use his or her
or its influence with a governmental entity or regulatory body to affect or influence any
act or decision of such governmental entity or regulatory body, in order to assist
Distributor or any of its Subsidiaries in obtaining or retaining business for or with, or
directing business to, any Person, or will do any of the foregoing.

ARTICLE 9

REGULATORY COMPLIANCE, CUSTOMER COMPLAINTS AND RECALL

     Section 9.1 No Modification. Distributor shall not modify, repackage, reformulate or
alter any Shipped Product, including its label, except with specific written authorization from
Supplier.

     Section 9.2 Customer Complaints. In the event either party receives a customer
complaint regarding Shipped Product, such party shall promptly notify the other of such complaint.
If the Shipped Product giving rise to such complaint was sold by Distributor, then Distributor
shall evaluate the complaint and promptly notify Supplier in writing regarding such evaluation.
Any adverse events shall be reported and handled as provided in the Pharmacovigilance Agreement
between the parties, a copy of which is attached to this Agreement as Exhibit A.

     Section 9.3 Event of Recall and Withdrawal. The parties’ responsibilities with regard
to any request, directive or order that Shipped Product be recalled or withdrawn issued or
impending from any governmental or regulatory authority in the Territory, or any court order of
competent jurisdiction orders such recall or withdrawal, or if either party reasonably
determines after consultation with the other that a recall or withdrawal is necessary or advisable
shall be controlled by the Pharmacovigilance Agreement.

ARTICLE 10

REPRESENTATIONS

     Section 10.1 Of Supplier. Supplier represents and warrants to Distributor as follows:

          (a) it is a corporation duly organized and validly existing under the laws of Delaware,
U.S.A.;

A-13

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

          (b) it has the power and authority to execute and deliver this Agreement and to perform
its obligations hereunder;

          (c) the execution, delivery and performance by it of this Agreement and its compliance
with the terms and provisions hereof does not and will not conflict with or result in a
breach of any other agreement or relationship; and

          (d) it has the right to transfer full unencumbered title to all Product sold to
Distributor under this Agreement.

     Section 10.2 Of Distributor. Distributor represents and warrants to Supplier as
follows:

          (a) it is a private company organized and validly existing under the federal laws of
Mexico;

          (b) it has the power and authority to execute and deliver this Agreement and to perform
its obligations hereunder; and

          (c) the execution, delivery and performance by it of this Agreement and its compliance
with the terms and provisions hereof does not and will not conflict with or result in a
breach of any other agreement or relationship.

ARTICLE 11

PRODUCT LIABILITY, INDEMNIFICATION, AND INSURANCE

     Section 11.1 Indemnification by Supplier. Supplier will indemnify, defend and hold
harmless Distributor, its Affiliates, and each of its and their respective employees, officers,
directors and agents (each, a “Distributor Indemnified Party”) from and against any and all
losses, damages, liabilities, settlements, penalties, fines, and expenses (including, without
limitation, reasonable attorneys’ fees and expenses) (collectively, “Liability”) that the
Distributor Indemnified Party may be required to pay to one or more Third Parties to the extent resulting
from or arising out of:

     (a) any Supplier representation or warranty set forth in this Agreement being untrue in
any material respect when made or any material breach by Supplier of any of its covenants or
obligations hereunder;

     (b) gross negligence or willful misconduct of Supplier; or

     (c) except, in each case, to the extent caused by the gross negligence or willful
misconduct of Distributor or any Distributor Indemnified Party, or by breach of this
Agreement by Distributor.

     Section 11.2 Indemnification by Distributor. Distributor will indemnify, defend and
hold harmless Supplier, its Affiliates, Sublicensees, distributors and each of its and their
respective employees, officers, directors and agents (each, a “Supplier Indemnified Party”)
from

A-14

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

and against any and all Liabilities that the Supplier Indemnified Party may be required to pay
to one or more Third Parties to the extent resulting from or arising out of:

     (a) any Distributor representation or warranty set forth in this Agreement being untrue
in any material respect when made or a material breach by Distributor of any of its
covenants or obligations hereunder;

     (b) gross negligence or willful misconduct of Distributor; or

     (c) except in each case, to the extent caused by the gross negligence or willful
misconduct of Supplier or any Supplier Indemnified Party, or by breach of this Agreement by
Supplier.

     Section 11.3 Product Liability Claims. Notwithstanding anything to the contrary
contained in Article 8 of this Agreement, the parties intend for the customer(s) of all Product to
provide indemnification to Distributor and Supplier for any product liability claim that may arise
from the sale or use of Product. Distributor shall use its best efforts to obtain covenants of
indemnification for all such product liability claims, but shall not be responsible for product
liability claims by virtue of its inability to obtain such indemnification despite its best
efforts.

     Section 11.4 Procedure. Each Party will notify the other in the event it becomes aware
of a claim for which indemnification may be sought hereunder or for which Liability is shared
pursuant to this Article 8. In case any proceeding (including any governmental investigation) is
instituted involving any Party in respect of which indemnity may be sought pursuant to this Article
8 such Party (the “Indemnified Party”) will promptly notify the other Party (the
“Indemnifying Party”) in writing and the Indemnifying Party and Indemnified Party will meet
to discuss how to respond to any claims that are the subject matter of such proceeding. The
Indemnifying Party, upon request of the Indemnified Party, will retain counsel reasonably
satisfactory to the Indemnified Party to represent the Indemnified Party and will pay the fees and
expenses of such counsel related to such proceeding. In any such proceeding, the Indemnified
Party will have the right to retain its own counsel, but the fees and expenses of such counsel will
be at the expense of the Indemnified Party unless (i) the Indemnifying Party and the Indemnified
Party will have mutually agreed to the retention of such counsel and payment of fees and expenses
or (ii) the named parties to any such proceeding (including any impleaded parties) include both the
Indemnifying Party and the Indemnified Party and representation of both Parties by the same counsel
would be inappropriate due to actual or potential differing interests between them. All such fees
and expenses incurred pursuant to Section 8.1 or Section 8.2 will be reimbursed as they are
incurred. The Indemnifying Party will not be liable for any settlement of any proceeding unless
effected with its written consent. The Indemnifying Party will not, without the written consent of
the Indemnified Party, effect any settlement of any pending or threatened proceeding in respect of
which the Indemnified Party is, or arising out of the same set of facts could have been, a party
and indemnity could have been sought hereunder by the Indemnified Party, unless such settlement
includes an unconditional release of the Indemnified Party from all liability on claims to which
the indemnity relates that are the subject matter of such proceeding.

A-15

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     Section 11.5 Insurance. Each Party shall obtain and maintain, during the Term of this
Agreement, commercial general liability insurance, including but not limited to products liability
and clinical insurance, with reputable and financially secure insurance carriers to cover its
indemnification obligations under Section 8.1 or Section 8.2as applicable, or self-insurance, with
limits of not less than 5 million U.S. dollars per occurrence and 10 million U.S. dollars in the
aggregate. Each Party shall list the other Party as an additional insured party on the insurance
policies described in this Section 8.5.

     Section 11.6 Liability Limitations. NOTWITHSTANDING THE FOREGOING, IN NO EVENT WILL
EITHER PARTY BE LIABLE TO THE OTHER FOR ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE,
OR EXEMPLARY DAMAGES UNDER THIS AGREEMENT, EXCEPT TO THE EXTENT THE DAMAGES RESULT FROM A PARTY’S
WILLFUL MISCONDUCT OR ARISE FROM A PARTY’S INDEMNIFICATION OBLIGATIONS UNDER THIS Article 8.

ARTICLE 12

CONFIDENTIALITY

     Section 12.1 Confidential Information. Except to the extent expressly permitted by
this Agreement and subject to the provisions of Section 3.1(b) and Section 3.1(c) at all times
during the Term and for five years following the expiration or termination of this Agreement, each
Party (a “Receiving Party”) (a) will keep completely confidential and will not publish or
otherwise disclose any Confidential Information furnished to it by the other Party (a
“Disclosing Party”), except to those of the Receiving Party’s employees, Affiliates,
consultants or representatives who have a need to know such information (collectively,
“Authorized Recipients”) to perform such Party’s obligations hereunder and (b) will not use
Confidential Information of the Disclosing Party directly or indirectly for any purpose other than
performing its obligations hereunder. The Receiving Party will be liable for any breach by any of
its Authorized Recipients of the restrictions set forth in this Agreement. Notwithstanding the
foregoing, Supplier may disclose Confidential Information of Distributor to Third Party Licensees
to the extent necessary to comply with or conduct activities under written arrangements with such
Third Party Licensees provided that such arrangements include obligations of confidentiality.

     Section 12.2 Exceptions to Confidentiality. The Receiving Party’s obligations set
forth in this Agreement will not extend to any Confidential Information of the Disclosing Party:

     (i) that is or hereafter becomes part of the public domain through no wrongful
act, fault or negligence on the part of a Receiving Party or its Authorized
Recipients;

     (ii) that is received from a Third Party without restriction and without breach
of any agreement or fiduciary duty between such Third Party and the Disclosing
Party;

A-16

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     (iii) that the Receiving Party can demonstrate by competent evidence was
already in its possession without any limitation or restriction on use or disclosure
prior to its receipt from the Disclosing Party;

     (iv) that is generally made available to Third Parties by the Disclosing Party
without any restriction imposed by the Disclosing Party on disclosure, whether such
restriction is by contract, fiduciary duty or by operation of law; or

     (v) that the Receiving Party can demonstrate by competent evidence was
independently developed by the Receiving Party without any reference to Confidential
Information.

     Section 12.3 Authorized Disclosure. Each Party and its Authorized Recipients may
disclose Confidential Information to the extent that such disclosure is made in response to a valid
order, governmental inquiry, or request (each an “Order”) of a court of competent
jurisdiction or other agency, as applicable; provided, however, that the Receiving Party must first
have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity
to quash such Order or to obtain a protective order requiring that the Confidential Information
and/or documents that are the subject of such Order be held in confidence by such court or agency
or, if disclosed, be used only for the purposes for which the Order was issued; and provided
further that if an Order is not quashed or a protective order is not obtained, the Confidential
Information disclosed in response to such Order will be limited to that information that is legally
required to be disclosed in such response to such Order.

     Section 12.4 Notification. The Receiving Party will notify the Disclosing Party
immediately, and cooperate with the Disclosing Party as the Disclosing Party may reasonably
request, upon the Receiving Party’s discovery of any loss or compromise of the Disclosing Party’s
Confidential Information.

     Section 12.5 Destruction of Confidential Information. Upon the expiration or earlier
termination of this Agreement, the Receiving Party will (a) destroy all tangible embodiments of
Confidential Information of the Disclosing Party, including any and all copies thereof, and those
portions of any documents, memoranda, notes, studies, and analyses prepared by the Receiving Party
or its Authorized Recipients that contain, incorporate, or are derived from such Confidential
Information and provide written certification of such destruction to the Disclosing Party in a form
reasonably acceptable to the Disclosing Party, provided that the legal department of the Receiving
Party will have the right to retain one copy of any such tangible embodiments for archival
purposes, provided such copy will continue to be maintained on a confidential basis subject to the
terms of this Agreement, and (b) immediately cease, and will cause its Authorized Recipients to
cease, use of such Confidential Information as well as any information or materials that contain,
incorporate, or are derived from such Confidential Information.

     Section 12.6 Use of Name and Disclosure of Terms. Each Party will keep the existence
of, the terms of, and the transactions covered by this Agreement confidential and will not disclose
such information to any other Person through a press release or otherwise, or mention or otherwise
use the name, insignia, symbol, trademark, trade name, or logotype of the other Party

A-17

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

or its
Affiliates in any manner without the prior written consent of the other Party in each instance
(which will not be unreasonably withheld). The restrictions imposed by this Section 3.1(f) will not
prohibit either Party from making any disclosure that is required by applicable law, rule, or
regulation or the requirements of a national securities exchange or another similar regulatory body
including disclosing such information in any clinical trial database maintained by or on behalf of
a Party. Further, the restrictions imposed on each Party under this Section 3.1(f) are not
intended, and will not be construed, to prohibit a Party from identifying the other Party in its
internal business communications, provided that any Confidential Information in such communications
remains subject to this Section 3.1(f).

     Section 12.7 Remedies. The Parties acknowledge and agree that the restrictions set
forth in this Article 12 are reasonable and necessary to protect the legitimate interests of the
Parties and that neither Party would have entered into this Agreement in the absence of such
restrictions, and that any breach or threatened breach of any provision of this Article 12 will
result in irreparable injury to the other Party for which there will be no adequate remedy at law.
In the event of a breach or threatened breach of any provision of Article 12 by a Party, the other
Party will be authorized and entitled to obtain from any court of competent jurisdiction injunctive
relief, whether preliminary or permanent, specific performance and an equitable accounting of all
earnings, profits and other benefits arising from such breach, which rights will be cumulative and
in addition to any other rights or remedies to which such Party may be entitled in law or equity.
The breaching Party agrees to waive any requirement that the non-breaching Party (i) post a bond or
other security as a condition for obtaining any such relief and (ii) show irreparable harm,
balancing of harms, consideration of the public interest or inadequacy of monetary damages as a
remedy. Nothing in this Section 3.1(g) is intended, or will be construed, to limit the Parties’
rights to equitable relief or any other remedy for a breach of any provision of this Agreement.

     Section 12.8 Survival. The provisions of this Article shall survive the expiration or
sooner termination of this Agreement.

ARTICLE 13

TERM AND TERMINATION

     Section 13.1 Term. The term of this Agreement shall commence on the Effective Date
and will remain in effect until December 31, 2010, unless terminated earlier under the provisions
herein (the “Term”).

     Section 13.2 Termination for Cause.

     (a) Termination for Material Breach. This Agreement may be terminated
effective immediately by written notice by a Party at any time during the Term if the other
Party materially breaches this Agreement, which breach remains uncured for 30 days measured
from the date written notice of such breach is given to the breaching Party. Such notice
must specify the nature of the breach and demand its cure; provided, however, that if such
breach is not capable of being cured within the stated period and the

A-18

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

breaching Party uses
Commercially Reasonable Efforts to cure such breach during such period and presents a
mutually agreeable remediation plan for such breach, this Agreement will not terminate and
the cure period will be extended for such period provided in the remediation plan as long as
the breaching party continues to use Commercially Reasonable Efforts to pursue the cure as
provided in such remediation plan. Notwithstanding anything to the contrary set forth in
this Agreement, but subject to the limitations on liability set forth in Articles 8 and 11,
termination will not be deemed to relieve a defaulting Party from any liability arising from
such default.

     (b) Violation of Law. This Agreement may be terminated by Novavax on giving 15
days’ written notice to Avimex, which will be effective on the expiration date of such 15
day period in the event that the Avimex or any of its Affiliates are convicted of a felony
for violating, or a final, non-appealable order is issued by a court of competent
jurisdiction finding that Avimex or any of its Affiliates violated, any Applicable Laws, the
Federal Foreign Corrupt Practices Act (or analogous law) or any securities laws or
regulations (collectively, the “Relevant Laws”), which are of such a nature that such
violation of such Relevant Laws would prevent or substantially diminish either Party from
performing or having the ability to perform its obligations pursuant to this Agreement.
Such notice of termination must be given within 15 days of Novavax becoming aware of the
circumstances described in this Section 13.2(b).

     (c) Bankruptcy. This Agreement may be terminated by written notice by either
Party at any time during the Term of this Agreement if the other Party will file in any
court or agency, pursuant to any statute or regulation of any state or country, a petition
in bankruptcy or insolvency or for reorganization or for an arrangement or for the
appointment of a receiver or trustee of that Party or of its assets, or if the other Party
proposes a written agreement of composition or extension of its debts, or if the other Party
will be served with an involuntary petition against it, filed in any insolvency proceeding,
and such petition is not dismissed within 60 days after the filing thereof, or if the other
Party proposes or is a Party to any dissolution or liquidation, or if the other Party makes
an assignment for the benefit of its creditors.

     Section 13.3 Rights and Duties on Termination. On termination of this Agreement:

          (a) Distributor shall have no further right to purchase or sell Product; provided,
however, that Distributor to and Supplier may agree to wind-down provisions allowing
Distributor to sell, or return Supplier, Product in its inventory or placed at customer
locations, after termination of this Agreement; and

          (b) Supplier shall have the right to retain any sums already paid by Distributor under
this Agreement, and Distributor shall pay all sums accrued that are then due under this
Agreement.

     Section 13.4 Survival of Certain Obligations. Expiration or termination of this
Agreement will not relieve the Parties of any obligation accruing before such expiration or
termination. The provisions of this Agreement that must, by their nature, survive expiration or

A-19

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

termination of this Agreement to give effect to their intent, will so survive, including without
limitation Articles 11 and 12 and Sections 7.2, 14.1, 14.2, 14.5 and 14.13. Any expiration or
early termination of this Agreement will be without prejudice to the rights of either Party against
the other accrued or accruing under this Agreement before termination.

ARTICLE 14

MISCELLANEOUS.

     Section 14.2 Governing Law; Jurisdiction; Dispute Resolution.

     (a) Governing Law. The interpretation and construction of this Agreement will
be governed by the laws of the State of Maryland, excluding any conflicts or choice of law
rule or principle that might otherwise refer construction or interpretation of this
Agreement to the substantive law of another jurisdiction.

     (b) Dispute Resolution. In the event of a dispute arising out of or relating to
this Agreement, either Party will provide written notice of the dispute to the other, in
which event the dispute will be referred to the executive officers designated below or their
successors, for attempted resolution by good faith negotiations within 15 days after such
notice is received. The initial designated officers (“Initial Officers”) are
initially as follows:

	 	For Novavax: 	 	Its Chief Executive Officer
	 
	 	For Avimex: 	 	Its Chief Executive Officer

          If the Initial Officers are unable to resolve the dispute within 10 days, the matter shall be
referred to the following:

	 	For Novavax: 	 	Its Chairman of the Board
	 
	 	For Avimex: 	 	Its Chairman of the Board

In the event the Chairmen of the Boards do not resolve such dispute within 5 days of the dispute
being elevated to their review, either Party may, after the expiration of the 15 day period from
receipt of the notice, seek to resolve the dispute through arbitration in accordance with Section
15.2.

     Section 14.2 Arbitration.

     (a) Arbitration Claims. Any claim, dispute, or controversy of whatever nature
arising between the Parties out of or relating to this Agreement that is not resolved under
Section 9.1(b) within the required 30 day time period, including without limitation, any
action or claim based on tort, contract, or statute (including any claims of breach or
violation of statutory or common law protections from discrimination, harassment and hostile
working environment), or concerning the interpretation, effect, termination,

A-20

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

validity,
performance and/or breach of this Agreement (“Arbitration Claim”), will be
resolved by final and binding arbitration before a single expert with relevant industry
experience selected by the Parties or, if the Parties cannot agree within ten (10) days, a
panel of three experts with relevant industry experience (each, an “Arbitrator”).
The panel of three Arbitrators shall be appointed in accordance with the Rules of
Arbitration of the International Chamber of Commerce. The Arbitration will be administered
under the Rules of Arbitration of the International Chamber of Commerce (the
“Administrator”). The arbitration will be held in Mexico City, Mexico and conducted
in English. The Arbitrators will be instructed by the Parties to complete the arbitration
within 90 days after selection of the final Arbitrator.

     (b) Arbitrators’ Award. The Arbitrators will, within 15 calendar days after the
conclusion of the arbitration hearing, issue a written award and statement of decision
describing the essential findings and conclusions on which the award is based, including the
calculation of any damages awarded. The decision or award rendered by the Arbitrators will
be final and non-appealable, and judgment may be entered upon it in accordance with
applicable law in any court of competent jurisdiction. The Arbitrators will be authorized
to award compensatory damages, but will NOT be authorized (i) to award non-economic damages,
such as for emotional distress, pain and suffering or loss of consortium, (ii) to award
punitive damages, or (iii) to reform, modify or materially change this Agreement or any
other agreements contemplated hereunder; provided, however, that the damage
limitations described in parts (i) and (ii) of this sentence will not apply if such damages
are statutorily imposed.

     (c) Costs. Each Party will bear its own attorney’s fees, costs, and
disbursements arising out of the arbitration and the costs of the arbitrator selected by it,
and will pay an equal share of the fees and costs of the third arbitrator; provided,
however, the Arbitrators will be authorized to determine whether a party is the
prevailing party, and if so, to award to that prevailing party reimbursement for its
reasonable attorneys’ fees, costs and disbursements (including, for example, expert witness
fees and expenses, photocopy charges, travel expenses, etc.), and/or the fees and costs of
the Administrator and the Arbitrators.

     (d) Compliance with this Agreement. Unless the Parties otherwise agree in
writing, during the period of time that any arbitration proceeding is pending under this
Agreement, the Parties will continue to comply with all those terms and provisions of this
Agreement that are not the subject of the pending arbitration proceeding.

     (e) Injunctive or Other Equity Relief. Nothing contained in this Agreement
will deny any Party the right to seek injunctive or other equitable relief from a court of
competent jurisdiction in the context of a bona fide emergency or prospective irreparable
harm, and such an action may be filed and maintained notwithstanding any ongoing arbitration
proceeding.

     Section 14.3 Force Majeure. No liability will result from, and no right to terminate
will arise, in whole or in part, based upon any delay in performance or non-performance, in whole
or

A-21

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

in part, by either of the Parties to this Agreement to the extent that such delay or
non-performance is caused by an event of Force Majeure. “Force Majeure” means an event
that is beyond the reasonable control of a non-performing Party (the “Force Majeure
Party”), including an act of God, act of the other Party, war, riot, civil commotion, terrorist
act, malicious damage, epidemic, quarantine, fire, flood, storm, natural disaster or compliance
with any law or governmental order, rule, regulation or direction, whether or not it is later held
to be invalid or inapplicable. The Force Majeure Party will within ten days of the occurrence of
the Force Majeure event, give written notice to the other Party stating the nature of the Force
Majeure event, its anticipated duration and any action being taken to avoid or minimize its effect.
Any suspension of performance will be of no greater scope and of no longer duration than is
reasonably required and the Force Majeure Party will use reasonable effort to remedy its inability
to perform; provided, however, if the suspension of performance continues or is anticipated to
continue for 30 days after the date of the occurrence, the unaffected Party will have the right but
not the obligation to perform on behalf of the Force Majeure Party for a period of such Force
Majeure and such additional period as may be reasonably required to assure a smooth and
uninterrupted transition of such activities. If such failure to perform would constitute a
material breach of this Agreement in the absence of such event of Force Majeure, and continues for
six months from the date of the occurrence and the Parties are not able to agree on appropriate
amendments within such period, such other Party will have the right, notwithstanding the first
sentence of this Section 14.3, to terminate this Agreement immediately by written notice to the
Force Majeure Party, in which case neither Party will have any liability to the other except for
those rights and liabilities that accrued prior to the date of termination and the consequences of
termination pursuant to Section 13.3, as if such termination was a termination as to which such
consequences applied.

     Section 14.4 Waiver and Non-Exclusion of Remedies. A Party’s failure to enforce, at
any time or for any period of time, any provision of this Agreement, or to exercise any right or
remedy will not constitute a waiver of that provision, right or remedy or prevent such Party from
enforcing any or all provisions of this Agreement and exercising any rights or remedies. To be
effective any waiver must be in writing. The rights and remedies provided in this Agreement are
cumulative and do not exclude any other right or remedy provided by law or otherwise available
except as expressly set forth in this Agreement.

     Section 14.5 Notices.

     (a) Notice Requirements. Any notice, request, demand, waiver, consent, approval
or other communication permitted or required under this Agreement must be in
writing, must refer specifically to this Agreement and will be deemed given only if
delivered by hand or sent by facsimile transmission (with transmission confirmed) or by
internationally recognized overnight delivery service that maintains records of delivery,
addressed to the Parties at their respective addresses specified in Section 9.6(b) or to
such other address as the Party to whom notice is to be given may have provided to the other
Party in accordance with this Section 9.6(a). Such Notice will be deemed to have been given
as of the date delivered by hand or transmitted by facsimile (with transmission confirmed)
or on the second business day (at the place of delivery) after deposit with an

A-22

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

internationally recognized overnight delivery service. This Section 9.6(a) is not intended
to govern the day-to-day business communications necessary between the Parties in performing
their obligations under the terms of this Agreement.

	 	(b)	 	Address for Notice.

For Novavax:

Novavax, Inc.

9920 Belward Campus Drive

Rockville, MD 20850

United States

Fax: 240-268-2148

Attn: Senior Vice President, International

          and Government Alliances

With a copy to:

Ballard Spahr LLP

1735 Market Street, 51st Floor

Philadelphia, PA 19103

Fax: 215-864-9073

Attn: Jennifer Miller

For Avimex:

Laboratorio Avi-Mex S.A. de C.V.

Maiz #18. Col. Granjas Esmeralda CP 09810

Mexico City, Mexico

Fax: (55) 54450462

Attn: Bernardo Lozano Dubernard, Director General

     Section 14.6 Entire Agreement. This Agreement, constitutes the entire agreement between the
Parties with respect to the subject matter of this Agreement. This Agreement supersedes all prior
agreements, whether written or oral, with respect to the subject matter of this Agreement. Each
Party confirms that it is not relying on any representations, warranties or covenants of the other
Party except as specifically set out in this Agreement. Nothing in this Agreement is intended to
limit or exclude any liability for fraud. All Exhibits or Schedules referred to in this Agreement
are intended to be and are hereby specifically incorporated into and
made a part of this Agreement. In the event of any inconsistency between any such Exhibits or
Schedules and this Agreement, the terms of this Agreement will govern.

     Section 14.7 Amendment. Any amendment or modification of this Agreement must be in writing and
signed by authorized representatives of both Parties.

     Section 14.8 Assignment. Distributor may not assign its rights or delegate its
obligations under this Agreement, in whole or in part, by operation of law, via a Change in
Control, or otherwise, without the prior written consent of Supplier which can be given or withheld
in Supplier’s discretion. Supplier may not assign its rights or delegate its obligations

A-23

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

under
this Agreement, in whole or in part, without the consent of Distributor, provided, however, that
this Agreement may be assigned by Supplier in connection with a Change in Control.

     Section 14.9 No Benefit to Others. The provisions of this Agreement are for the sole
benefit of the Parties and their successors and permitted assigns, and they will not be construed
as conferring any rights in any other persons except as otherwise expressly provided in this
Agreement.

     Section 14.10 Counterparts. This Agreement may be executed in any number of
counterparts, each of which will be deemed an original and all of which taken together will be
deemed to constitute one and the same instrument. An executed signature page of this Agreement
delivered by facsimile transmission will be as effective as an original executed signature page.

     Section 14.11 Severability. To the fullest extent permitted by applicable law, the
Parties waive any provision of law that would render any provision in this Agreement invalid,
illegal or unenforceable in any respect. If any provision of this Agreement is held to be invalid,
illegal or unenforceable, in any respect, then such provision will be given no effect by the
Parties and will not form part of this Agreement. To the fullest extent permitted by applicable
law and if the rights or obligations of any Party will not be materially and adversely affected,
all other provisions of this Agreement will remain in full force and effect and the Parties will
use their best efforts to negotiate a provision in replacement of the provision held invalid,
illegal or unenforceable that is consistent with applicable law and achieves, as nearly as
possible, the original intention of the Parties.

     Section 14.12 Further Assurance. Each Party will perform all further acts and things
and execute and deliver such further documents as may be necessary or as the other Party may
reasonably require to implement or give effect to this Agreement.

     Section 14.13 Publicity. It is understood that the Parties will issue a press release
announcing the execution of this Agreement in such form as the Parties mutually agree. The Parties
will consult with each other reasonably and in good faith with respect to the text and timing of
any subsequent press releases relating to this Agreement or the activity hereunder prior to the
issuance thereof, provided that a Party may not unreasonably withhold consent to such releases, and
that either Party may issue such press releases as it determines, based on advice of
counsel, are reasonably necessary to comply with laws or regulations or for appropriate market
disclosure or which are consistent with information disclosed in prior releases properly made
hereunder.

[SIGNATURES ON THE FOLLOWING PAGE.]

A-24

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

     IN WITNESS WHEREOF, duty authorized representatives of the Parties have duly executed this
Agreement to be effective as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 	 	 
	NOVAVAX, INC.	 	 	 	LABORATORIO AVI-MEX, S.A. DE C.V.
	 
	 	 	 	 	 	 	 	 	 	 	 	 
	By:

	 	 	 	 	 	 	 	By:	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 

	 	Name:
	 	 	 	 	 	 	 	Name:	 	 
	 

	 	 	 	 
	 	 	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 	 	 	 	Title:	 	 

A-25

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

Exhibit A

Pharmacovigilance Agreement

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

Exhibit B

Use of Protocol Agreement

[* * *]

 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED

WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND

EXCHANGE COMMISSION.

Exhibit C

List of Latin American Countries

[* * *]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]